# U. S. SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549

	F	ORM 10-Q		
[X] QUARTERLY REPORT	Γ PURSUANT TO SECTION 13	OR 15(d) OF THE SECURITIES EXCHA	ANGE ACT OF 1934	
	For the quarterly pe	eriod ended December 31, 2009		
		OR		
[ ] TRANSITION REPORT	Γ PURSUANT TO SECTION 13	OR 15(d) OF THE SECURITIES EXCHA	ANGE ACT OF 1934	
	For the transition	n period from to		
	Commission 1	File Number: 001-32433		
	Presti	<b>ge</b> Brands		
		ANDS HOLDINGS, INC. strant as specified in its charter)		
<b>Delaware</b> (State or other jurisdiction incorporation or organization)		(I.R.S	<b>20-1297589</b> S. Employer Identification No.)	
	Irvingto	orth Broadway n, New York 10533 ecutive Offices, including zip code)		
		14) 524-6810 ne number, including area code)		
	or such shorter period that the Re	required to be filed by Section 13 or 15(d) or gistrant was required to file such reports), a		
	ule 405 of Regulation S-T (§ 232.	y and posted on its corporate Web site, if any 405 of this chapter) during the preceding 12		
		er, an accelerated filer, a non-accelerated file porting company" in Rule 12b-2 of the Excha		See
Large accelerated filer o	Accelerated filer x	Non-accelerated filer o	Smaller reporting company	0
Indicate by check mark whether the Re Yes o No x	gistrant is a shell company (as defi	ned in Rule 12b-2 of the Exchange Act).		
As of February 3, 2010, there were 50,	029,890 shares of common stock o	utstanding.		

# Prestige Brands Holdings, Inc. Form 10-Q Index

# PART I. FINANCIAL INFORMATION

Item 1.	Consolidated Financial Statements	
	Consolidated Statements of Operations – three and nine month periods	2
	ended December 31, 2009 and 2008 (unaudited)	
	Consolidated Balance Sheets – December 31, 2009 and March 31, 2009 (unaudited)	3
	Consolidated Statements of Cash Flows – nine month periods ended	4
	December 31, 2009 and 2008 (unaudited)	
	Notes to Consolidated Financial Statements	5
Item 2.	Management's Discussion and Analysis of Financial Condition	29
	and Results of Operation	
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	48
Item 4.	Controls and Procedures	48
PART II.	OTHER INFORMATION	
111111111	OTHER IN ORDER TOOL	
Item 1.	Legal Proceedings	48
Item 6.	Exhibits	49
	Signatures	50
	Trademarks and Trade Names	
	Trademarks and trade names used in this Quarterly Report on Form 10-Q are the property of Prestige Brands Holdings, Inc.	
	or its subsidiaries, as the case may be. We have italicized our trademarks or trade names when they appear in this Quarterly Report on Form 10-Q.	

# PART I FINANCIAL INFORMATION

# Item 1. CONSOLIDATED FINANCIAL STATEMENTS

# Prestige Brands Holdings, Inc. Consolidated Statements of Operations (Unaudited)

	Th	Three Months Ended December 31					Nine Months Ended December 31			
(In thousands, except share data)		2009		2008		2009		2008		
Revenues										
Net sales	\$	74,997	\$	77,345	\$	229,130	\$	232,582		
Other revenues		451		621		1,511		1,921		
Total revenues		75,448		77,966		230,641		234,503		
Cost of Sales										
Cost of sales		35,641		36,480		108,670		109,789		
Gross profit		39,807		41,486		121,971		124,714		
Operating Expenses										
Advertising and promotion		6,099		11,349		24,645		32,129		
General and administrative		7,411		8,311		26,088		25,647		
Depreciation and amortization		2,596		2,311		7,781		6,926		
Total operating expenses		16,106		21,971		58,514		64,702		
Operating income		23,701		19,515		63,457		60,012		
Other (income) expense										
Interest income		-		(14)		-		(143		
Interest expense		5,558		7,065		16,853		22,656		
Total other expense		5,558		7,051		16,853		22,513		
Income from continuing operations before income taxes		18,143		12,464		46,604		37,499		
Provision for income taxes		7,807		4,724		18,594		14,212		
Income from continuing operations		10,336		7,740		28,010		23,287		
Discontinued Operations										
Income from discontinued operations, net of income tax		87		278		661		1,034		
Gain on sale of discontinued operations, net of income tax		157		_		157		-		
Net income	\$	10,580	\$	8,018	\$	28,828	\$	24,321		
Basic earnings per share:										
Income from continuing operations	\$	0.21	\$	0.15	\$	0.56	\$	0.47		
Net income	\$	0.21	\$	0.16	\$	0.58	\$	0.49		
Diluted earnings per share:										
Income from continuing operations	\$	0.21	\$	0.15	\$	0.56	\$	0.47		
Net income	\$	0.21	\$	0.16	\$	0.58	\$	0.49		
Weighted average shares outstanding:										
Basic		50,030		49,960		50,008		49,921		
Diluted		50,074		50,040		50,078		50,038		
See accompanying notes.										

# Prestige Brands Holdings, Inc. Consolidated Balance Sheets (Unaudited)

Deferred income tax assets5,0454,022Prepaid expenses and other current assets2,0221,358Current assets of discontinued operations-1,038Total current assets106,039103,563	(In thousands) Assets	December 31, 2009		M	Iarch 31, 2009
Accounts receivable         36,025         36,025         10,025         25,939         25,939         Deferred income tax asserts         2,022         1,328         Current asserts         2,022         1,328         Current asserts of discontinued operations         1,035         1,0	Current assets				
Inventories	Cash and cash equivalents	\$	34,262	\$	35,181
Deferred income tax assets         5,045         4,022         1,328           Prepaid expenses and other current assets         2,022         1,328           Current assets of discontinued operations         106,039         103,563           Foral current assets         106,039         103,563           Property and equipment         11,249         114,240           Goodwill         114,240         161,240           Interpolity essets         561,828         569,137           Chord Lassets         3,170         4,602           Long-term assets of discontinued operations         -         8,722           Total Assets         \$786,574         \$80,331           Liabilities           Accounts payable         \$16,904         \$15,808           Accounts payable         \$16,904         \$15,808           Accounts payable         \$16,904         \$15,808           Accounted interest payable         \$15,909         \$15,808           Accounted interest payable         \$15,909         \$15,808           Accounted interest payable         \$15,909         \$15,808           Accountered interest payable         \$16,904         \$15,808           Accurrent liabilities         \$15,909         \$15,808	Accounts receivable		30,618		36,025
Prepaid expenses and other current assets         2,022         1,388           Current assets of discontinued operations         1,083         103,503           Total current assets         106,003         105,503           Property and equipment         1,297         1,367           Goodwill         114,240         114,240           Intangible assets         561,828         561,828           Other cong-term assets         3,170         4,602           Long-term assets of discontinued operations         3,770         8,472           Total Assets         \$786,574         \$ 80,333           Labilities and Stockholders' Equity           Current Labilities         \$15,904         \$ 15,898           Account payable         \$ 16,904         \$ 15,898           Account payable         \$ 15,909         \$ 15,898           Account payable         \$ 13,550         3,550           Other accrued liabilities         33,500         3,550           Total current liabilities         315,787         3,4787           Comparent deb         \$ 15,787         3,509           Total current liabilities         \$ 109,796         9,598           Total Liabilities         \$ 16,792         9,509 <t< td=""><td>Inventories</td><td></td><td>34,092</td><td></td><td>25,939</td></t<>	Inventories		34,092		25,939
Current assets of discontinued operations         1.038           Total current assets         106,039         103,038           Property and equipment         1,297         1,367           Goodwill         114,240         114,240           Intangible assets         561,828         569,137           Other long-term assets of discontinued operations         -         8,722           Total Assets         \$786,572         \$80,328           Liabilities and Stockholders' Equity           Current liabilities           Account payable         \$16,904         \$15,898           Accound interest payable         \$16,904         \$15,898           Account payable         \$16,904         \$15,898           Account payable         \$16,904         \$15,898           Account payable         \$16,904         \$15,898           Account payable         \$16,904         \$15,898           Accounted interest payable         \$16,904         \$15,898           Current portion of long-term debt         \$3,507         \$3,507           Total current liabilities         \$16,904         \$15,898           Cong-term debt         \$15,907         \$15,909           Cong-term debt         \$15,907         \$16,909<	Deferred income tax assets		5,045		4,022
Total current assets         106,035         103,563           Property and equipment         1,297         1,367           Goodwill         114,240         124,240         124,242         124,242         124,242         124,241         12,349         12,448         12,349         12,448         12,349         12,448         12,449         12,448         12,449         12,448			2,022		1,358
Property and equipment         1,297         1,367           Goodwill         114,240         114,240           Intangible assets         561,828         569,137           Other long-term assets         3,70         4,602           Long-term assets of discontinued operations         -         8,722           Total Assets         \$786,572         \$81,381           Liabilities and Stockholders' Equity           Current liabilities           Accrued interest payable         2,46         5,371           Accrued interest payable         2,46         5,371           Other accrued liabilities         31,258         9,407           Total current portion of long-term debt         3,550         3,550           Total current liabilities         36,159         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - S0.01 par value           Authorized - 5,000 shares         5           Lautorized - 5,001 par value         5           Authorized - 5,001 par value         5	Current assets of discontinued operations		_		1,038
Goodwill         114,240         114,240           Intangible asets         561,828         569,137           Other long-term assets         3,170         4,602           Long-term assets of discontinued operations         -         8,472           Total Assets         \$ 786,574         \$ 801,381           Liabilities           Accounts payable         \$ 16,904         \$ 15,898           Account payable         2,446         5,371           Other accrued inabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         315,787         374,787           Deferred income tax liabilities         315,787         374,787           Deferred income tax liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - 50,01 par value           Authorized - 5,000 shares         5           Issued and outstanding - None         5           Common stock - 50,01 par value         5           Authorized - 50,000 shares         5           Issued and outstanding - None         5	Total current assets		106,039		103,563
Goodwill         114,240         114,240           Intangible asets         561,828         569,137           Other long-term assets         3,170         4,602           Long-term assets of discontinued operations         -         8,472           Total Assets         \$ 786,574         \$ 801,381           Liabilities           Accounts payable         \$ 16,904         \$ 15,898           Account payable         2,446         5,371           Other accrued inabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         315,787         374,787           Deferred income tax liabilities         315,787         374,787           Deferred income tax liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - 50,01 par value           Authorized - 5,000 shares         5           Issued and outstanding - None         5           Common stock - 50,01 par value         5           Authorized - 50,000 shares         5           Issued and outstanding - None         5	Property and equipment		1,297		1,367
Other long-term assets         3,170         4,602           Long-term assets of discontinued operations         - 8,472           Total Assets         \$ 786,574         \$ 801,381           Liabilities and Stockholders' Equity           Current liabilities           Accounts payable         \$ 16,904         \$ 15,898           Accounts payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         35,55         3,550           Total current liabilities         315,787         374,787           Deferred income tax liabilities         119,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Freferred stock – 5,001 par value           Authorized – 5,000 shares           Issued and outstanding – None         5         5           Common stock – 5,001 par value         5         5           Authorized – 5,000 shares         5         5           Issued and outstanding – None         5         5           Common stock – 5,001 par value         5         5<			114,240		114,240
Other long-term assets         3,170         4,602           Long-term assets of discontinued operations         - 8,472           Total Assets         \$ 786,574         \$ 801,381           Liabilities and Stockholders' Equity           Current liabilities           Accounts payable         \$ 16,904         \$ 15,898           Accounts payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         35,55         3,550           Total current liabilities         315,787         374,787           Deferred income tax liabilities         119,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Freferred stock – 5,001 par value           Authorized – 5,000 shares           Issued and outstanding – None         5         5           Common stock – 5,001 par value         5         5           Authorized – 5,000 shares         5         5           Issued and outstanding – None         5         5           Common stock – 5,001 par value         5         5<	Intangible assets				
Long-term assets of discontinued operations         -         8,472           Total Assets         \$ 786,574         \$ 801,381           Liabilities and Stockholders' Equity           Current liabilities           Accounts payable         \$ 16,904         \$ 15,898           Account interest payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         36,559         3,550           Coll current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Freferred stock – \$0.01 par value           Authorized – \$0.000 shares           Issued – \$0.01 par value           Authorized – \$0.01 par value         \$ 5           Authorized – \$0.01 par value         \$ 5           Suppose – \$0.01 par value         \$ 5           Authorized – \$0.01 par value         \$ 5           Suppose – \$0.01 par value					
Carrent liabilities and Stockholders' Equity   Current liabilities			-		
Current liabilities         \$ 16,904         \$ 15,898           Accounts payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,933           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock – \$0.01 par value         4461,721         506,996           Authorized – \$5,000 shares         5         5           Issued and outstanding – None         5         5           Common stock – \$0.01 par value         5         5           Authorized – \$5,000 shares         5         5           Issued – \$0,154 shares at December 31, 2009 and \$50,600 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost – 124 shares at December 31, 2009         63         63           and March 31, 2009         63         63	Total Assets	\$	786,574	\$	801,381
Current liabilities         \$ 16,904         \$ 15,898           Accounts payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,933           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock – \$0.01 par value         4461,721         506,996           Authorized – \$5,000 shares         5         5           Issued and outstanding – None         5         5           Common stock – \$0.01 par value         5         5           Authorized – \$5,000 shares         5         5           Issued – \$0,154 shares at December 31, 2009 and \$50,600 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost – 124 shares at December 31, 2009         63         63           and March 31, 2009         63         63	Liabilities and Stockholdows' Equity				
Accounts payable         \$ 16,904         \$ 15,898           Accrued interest payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock – \$0,01 par value           Authorized – \$0,00 shares         461,721         506,996           Authorized – \$0,01 par value         461,721         501,24           Authorized – \$0,01 par value         501,24         501           Sused – \$0,154 shares at December 31, 2009 and \$0,060 shares at March 31, 2009         50         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost – 124 shares at December 31, 2009         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated other comprehensive loss         <	• •				
Accrued interest payable         2,446         5,371           Other accrued liabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         36,158         34,226           Long-term debt         109,776         97,983           Deferred income tax liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - \$0.01 par value           Authorized - 5,000 shares           Issued and outstanding - None           Common stock - \$0.01 par value         400,000 shares           Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost - 124 shares at December 31, 2009         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385		¢	16 004	¢	15 000
Other accrued liabilities         13,258         9,407           Current portion of long-term debt         3,550         3,550           Total current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - \$0.01 par value           Authorized - 5,000 shares         18.50 et al. (19,100 et al.)           Issued and outstanding - None         502         501           Common stock - \$0.01 par value         401         383,600         382,803           Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost - 124 shares at December 31, 2009         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385		Ą		φ	
Current portion of long-term debt         3,550         3,550           Total current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock – \$0.01 par value           Authorized – 5,000 shares         8           Issued and outstanding – None         8           Common stock – \$0.01 par value         5           Authorized – 250,000 shares         5           Issued – 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009         \$50         \$51           Additional paid-in capital         383,600         382,803           Treasury stock, at cost – 124 shares at December 31, 2009         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385					
Total current liabilities         36,158         34,226           Long-term debt         315,787         374,787           Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - \$0.01 par value           Authorized - 5,000 shares         1           Issued and outstanding - None         Common stock - \$0.01 par value           Authorized - 250,000 shares         502         501           Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost - 124 shares at December 31, 2009         (63)         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385					
Long-term debt       315,787       374,787         Deferred income tax liabilities       109,776       97,983         Total Liabilities       461,721       506,996         Commitments and Contingencies – Note 16         Stockholders' Equity         Preferred stock - \$0.01 par value         Authorized - 5,000 shares         Issued and outstanding - None         Common stock - \$0.01 par value         Authorized - 250,000 shares         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost - 124 shares at December 31, 2009       63       63         and March 31, 2009       (63)       (63)       63         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated other comprehensive loss       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385	•			_	
Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - \$0.01 par value           Authorized - 50,000 shares         5           Issued and outstanding - None         5           Common stock - \$0.01 par value         4           Authorized - 250,000 shares         502         501           Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost - 124 shares at December 31, 2009         (63)         (63)           and March 31, 2009         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385	Total current Habilities		30,158		34,226
Deferred income tax liabilities         109,776         97,983           Total Liabilities         461,721         506,996           Commitments and Contingencies – Note 16           Stockholders' Equity           Preferred stock - \$0.01 par value           Authorized - 50,000 shares         5           Issued and outstanding - None         5           Common stock - \$0.01 par value         4           Authorized - 250,000 shares         502         501           Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009         502         501           Additional paid-in capital         383,600         382,803           Treasury stock, at cost - 124 shares at December 31, 2009         (63)         (63)           and March 31, 2009         (63)         (63)           Accumulated other comprehensive loss         (492)         (1,334)           Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385	Long-term debt		315,787		374,787
Commitments and Contingencies – Note 16         Stockholders' Equity         Preferred stock - \$0.01 par value         Authorized - 5,000 shares         Issued and outstanding - None         Common stock - \$0.01 par value         Authorized - 250,000 shares         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost - 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (63)       (63)         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385	Deferred income tax liabilities		109,776		97,983
Stockholders' Equity         Preferred stock - \$0.01 par value         Authorized - 5,000 shares         Issued and outstanding - None         Common stock - \$0.01 par value         Authorized - 250,000 shares         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost - 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (63)       (63)         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385	Total Liabilities		461,721		506,996
Stockholders' Equity         Preferred stock - \$0.01 par value         Authorized - 5,000 shares         Issued and outstanding - None         Common stock - \$0.01 par value         Authorized - 250,000 shares         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost - 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (63)       (63)         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385	Commitments and Contingencies – Note 16				
Preferred stock - \$0.01 par value         Authorized - 5,000 shares         Issued and outstanding - None         Common stock - \$0.01 par value         Authorized - 250,000 shares         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost - 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (63)       (63)         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385					
Authorized - 5,000 shares  Issued and outstanding - None  Common stock - \$0.01 par value  Authorized - 250,000 shares  Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009  Additional paid-in capital  Treasury stock, at cost - 124 shares at December 31, 2009  and March 31, 2009  Accumulated other comprehensive loss  Accumulated deficit  Total Stockholders' Equity  Authorized - 5,000 shares  Solve					
Issued and outstanding - None       Common stock - \$0.01 par value         Authorized - 250,000 shares       Soz 501         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       383,600 382,803         Additional paid-in capital       383,600 382,803         Treasury stock, at cost - 124 shares at December 31, 2009 and March 31, 2009       (63) (63)         Accumulated other comprehensive loss       (492) (1,334)         Accumulated deficit       (58,694) (87,522)         Total Stockholders' Equity       324,853 294,385	•				
Common stock - \$0.01 par value         Authorized - 250,000 shares         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost – 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (492)       (1,334)         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385					
Authorized - 250,000 shares       302       501         Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       383,600       382,803         Additional paid-in capital       383,600       382,803         Treasury stock, at cost – 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (492)       (1,334)         Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385	<u> </u>				
Issued - 50,154 shares at December 31, 2009 and 50,060 shares at March 31, 2009       502       501         Additional paid-in capital       383,600       382,803         Treasury stock, at cost – 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (492)       (1,334)         Accumulated other comprehensive loss       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385					
Additional paid-in capital       383,600       382,803         Treasury stock, at cost – 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (63)       (492)       (1,334)         Accumulated other comprehensive loss       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385			502		501
Treasury stock, at cost – 124 shares at December 31, 2009       (63)       (63)         and March 31, 2009       (492)       (1,334)         Accumulated other comprehensive loss       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385					
Accumulated other comprehensive loss       (492)       (1,334)         Accumulated deficit       (58,694)       (87,522)         Total Stockholders' Equity       324,853       294,385	Treasury stock, at cost – 124 shares at December 31, 2009				
Accumulated deficit         (58,694)         (87,522)           Total Stockholders' Equity         324,853         294,385					
Total Stockholders' Equity 324,853 294,385					
Total Liabilities and Stockholders' Equity \$\frac{\$186,574}{}\$\$ \$\frac{\$801,381}{}\$\$	Total Stockholders Equity	<u></u>	324,033		234,305
	Total Liabilities and Stockholders' Equity	\$	786,574	\$	801,381

-3-

See accompanying notes.

# Prestige Brands Holdings, Inc. Consolidated Statements of Cash Flows (Unaudited)

# Nine Months Ended December 31

		31					
(In thousands)		2009		2008			
Operating Activities							
Net income	\$	28,828	\$	24,321			
Adjustments to reconcile net income to net cash provided by operating activities:							
Depreciation and amortization		8,679		8,273			
Gain on sale of discontinued operations		(253)		-			
Deferred income taxes		10,254		7,393			
Amortization of deferred financing costs		1,432		1,696			
Stock-based compensation		1,658		2,248			
Changes in operating assets and liabilities							
Accounts receivable		6,407		9,588			
Inventories		(8,281)		945			
Prepaid expenses and other current assets		(664)		(527)			
Accounts payable		1,006		(2,450)			
Accrued liabilities		1,424		1,860			
Net cash provided by operating activities		50,490		53,347			
Investing Activities		(400)		(205)			
Purchases of equipment		(402)		(397)			
Proceeds from sale of discontinued operations		7,993		- (4.404)			
Business acquisition purchase price adjustments	<u> </u>			(4,191)			
Net cash provided by (used for) investing activities		7,591	_	(4,588)			
Financing Activities							
Repayment of long-term debt		(59,000)		(26,887)			
Purchase of common stock for treasury		(85,000)		(16)			
Net cash used for financing activities		(59,000)		(26,903)			
		(55,555)	_	(==,===)			
Increase (Decrease) in cash		(919)		21,856			
Cash - beginning of period	_	35,181		6,078			
Cash - end of period	\$	34,262	\$	27,934			
	<u> </u>			·			
Interest paid	\$	18,345	\$	24,276			
Income taxes paid	\$	9,820	\$	7,251			

See accompanying notes.

# Prestige Brands Holdings, Inc. Notes to Consolidated Financial Statements

#### 1. Business and Basis of Presentation

#### **Nature of Business**

Prestige Brands Holdings, Inc. (referred to herein as the "Company" which reference shall, unless the context requires otherwise, be deemed to refer to Prestige Brands Holdings, Inc. and all of its direct or indirect wholly-owned subsidiaries on a consolidated basis) is engaged in the marketing, sales and distribution of over-the-counter healthcare, personal care and household cleaning brands to mass merchandisers, drug stores, supermarkets and club stores primarily in the United States, Canada and certain other international markets. Prestige Brands Holdings, Inc. is a holding company with no assets or operations and is also the parent guarantor of the senior credit facility and the senior subordinated notes more fully described in Note 9 to the consolidated financial statements.

#### **Basis of Presentation**

The unaudited consolidated financial statements presented herein have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. All significant intercompany transactions and balances have been eliminated. In the opinion of management, the financial statements include all adjustments, consisting of normal recurring adjustments that are considered necessary for a fair presentation of the Company's consolidated financial position, results of operations and cash flows for the interim periods. Operating results for the nine month period ended December 31, 2009 are not necessarily indicative of results that may be expected for the fiscal year ending March 31, 2010. This financial information should be read in conjunction with the Company's financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2009.

# **Use of Estimates**

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company's knowledge of current events and the Company's expectations, actual results could differ from those estimates. As discussed below, the Company's most significant estimates include those made in connection with the valuation of goodwill and intangible assets, sales returns and allowances, trade promotional allowances and inventory obsolescence.

#### Cash and Cash Equivalents

The Company considers all short-term deposits and investments with original maturities of three months or less to be cash equivalents. Substantially all of the Company's cash is held by a large regional bank with headquarters in California. The Company does not believe that, as a result of this concentration, it is subject to any unusual financial risk beyond the normal risk associated with commercial banking relationships.

#### Accounts Receivable

The Company extends non-interest bearing trade credit to its customers in the ordinary course of business. The Company maintains an allowance for doubtful accounts receivable based upon historical collection experience and expected collectability of the accounts receivable. In an effort to reduce credit risk, the Company (i) has established credit limits for all of its customer relationships, (ii) performs ongoing credit evaluations of customers' financial condition, (iii) monitors the payment history and aging of customers' receivables, and (iv) monitors open orders against an individual customer's outstanding receivable balance.

#### Inventories

Inventories are stated at the lower of cost or fair value, with cost determined by using the first-in, first-out method. The Company provides an allowance for slow moving and obsolete inventory, whereby it reduces

inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability, equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

#### **Property and Equipment**

Property and equipment are stated at cost and are depreciated using the straight-line method based on the following estimated useful lives:

	Years
Machinery	5
Computer equipment	3
Furniture and fixtures	7

Leasehold improvements are amortized over the lesser of the term of the lease or 5 years.

Expenditures for maintenance and repairs are charged to expense as incurred. When an asset is sold or otherwise disposed of, the cost and associated accumulated depreciation are removed from the accounts and the resulting gain or loss is recognized in the consolidated statement of operations.

Property and equipment are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

#### Goodwill

The excess of the purchase price over the fair market value of assets acquired and liabilities assumed in business acquisitions is classified as goodwill. The Company does not amortize goodwill, but performs impairment tests of the carrying value at least annually in the fourth fiscal quarter. The Company tests goodwill for impairment at the reporting unit "brand" level which is one level below the operating segment level.

#### Intanaible Assets

Intangible assets, which are composed primarily of trademarks, are stated at cost less accumulated amortization. For intangible assets with finite lives, amortization is computed on the straight-line method over estimated useful lives ranging from 3 to 30 years.

Indefinite-lived intangible assets are tested for impairment at least annually in the fourth fiscal quarter; however, at each reporting period an evaluation is made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are reviewed for impairment whenever events or changes in circumstances indicate that their carrying amounts exceed their fair values and may not be recoverable. An impairment loss is recognized if the carrying amount of the asset exceeds its fair value.

#### **Deferred Financing Costs**

The Company has incurred debt origination costs in connection with the issuance of long-term debt. These costs are capitalized as deferred financing costs and amortized using the straight-line method, which approximates the effective interest method, over the term of the related debt.

# Revenue Recognition

Revenues are recognized when the following criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the selling price is fixed or determinable; (iii) the product has been shipped and the customer takes ownership and assumes the risk of loss; and (iv) collection of the resulting receivable is reasonably assured. The Company has determined that these criteria are met and the transfer of the risk of loss generally occurs when product is received by the customer and, accordingly, recognizes revenue at that time. Provision is made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on the Company's historical experience.

As is customary in the consumer products industry, the Company participates in the promotional programs of its customers to enhance the sale of its products. The cost of these promotional programs varies based on the actual

number of units sold during a finite period of time. The Company estimates the cost of such promotional programs at their inception based on historical experience and current market conditions and reduces sales by such estimates. These promotional programs consist of direct to consumer incentives such as coupons and temporary price reductions, as well as incentives to the Company's customers, such as slotting fees and cooperative advertising. Estimates of the costs of these promotional programs reflect the Company's arrangements with its customers, and are based on (i) historical sales experience, (ii) the current offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results.

Due to the nature of the consumer products industry, the Company is required to estimate future product returns. Accordingly, the Company records an estimate of product returns concurrent with recording sales which is made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of the Company's product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

# Cost of Sales

Cost of sales includes product costs, warehousing costs, inbound and outbound shipping costs, and handling and storage costs. Shipping, warehousing and handling costs were \$6.0 million and \$16.0 million for the three and nine month periods ended December 31, 2009, respectively. During the three and nine month periods ended December 31, 2008, such costs were \$5.9 million and \$17.6 million, respectively.

# **Advertising and Promotion Costs**

Advertising and promotion costs are expensed as incurred. Slotting fees associated with products are recognized as a reduction of sales. Under slotting arrangements, the retailers allow the Company's products to be placed on the stores' shelves in exchange for such fees. Direct reimbursements of advertising costs are reflected as a reduction of advertising costs in the periods in which the reimbursement criteria are achieved.

#### Stock-based Compensation

The Company recognizes employee stock-based compensation by measuring the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is to be recognized over the period an employee is required to provide service in exchange for the award, generally referred to as the requisite service period.

#### **Income Taxes**

Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established when necessary to reduce deferred tax assets to the amounts expected to be realized.

The Taxes Topic of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") prescribes a recognition threshold and measurement attributes for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. As a result, the Company has applied a more-likely-than-not recognition threshold for all tax uncertainties. The guidance only allows the recognition of those tax benefits that have a greater than 50% likelihood of being sustained upon examination by the various taxing authorities.

The Company is subject to taxation in the United States and various state and foreign jurisdictions. The Company remains subject to examination by tax authorities for years after 2004.

The Company classifies penalties and interest related to unrecognized tax benefits as income tax expense in the Statements of Operations.

#### **Derivative Instruments**

Companies are required to recognize derivative instruments as either assets or liabilities in the consolidated Balance Sheets at fair value. The accounting for changes in the fair value of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and, further, on the type of hedging

relationship. For those derivative instruments that are designated and qualify as hedging instruments, a company must designate the hedging instrument, based upon the exposure being hedged, as a fair value hedge, a cash flow hedge or a hedge of a net investment in a foreign operation.

The Company has designated its derivative financial instruments as cash flow hedges because they hedge exposure to variability in expected future cash flows that are attributable to interest rate risk. For these hedges, the effective portion of the gain or loss on the derivative instrument is reported as a component of other comprehensive income (loss) and reclassified into earnings in the same line item (principally interest expense) associated with the forecasted transaction in the same period or periods during which the hedged transaction affects earnings. Any ineffective portion of the gain or loss on the derivative instruments is recorded in results of operations immediately. Cash flows from these instruments are classified as operating activities.

#### Earnings Per Share

Basic earnings per share is calculated based on income available to common stockholders and the weighted-average number of shares outstanding during the reporting period. Diluted earnings per share is calculated based on income available to common stockholders and the weighted-average number of common and potential common shares outstanding during the reporting period. Potential common shares, composed of the incremental common shares issuable upon the exercise of stock options, stock appreciation rights and unvested restricted shares, are included in the earnings per share calculation to the extent that they are dilutive.

#### Reclassifications

Certain prior period financial statement amounts have been reclassified to conform to the current period presentation.

#### **Recently Issued Accounting Standards**

In January 2010, the FASB issued authoritative guidance requiring new disclosures and clarifying some existing disclosure requirements about fair value measurement. Under the new guidance, a reporting entity should (a) disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and describe the reasons for the transfers, and (b) present separately information about purchases, sales, issuances, and settlements in the reconciliation for fair value measurements using significant unobservable inputs. This guidance is effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. The Company does not expect this guidance to have a material impact on its consolidated financial statements.

In August 2009, the FASB issued authoritative guidance to provide clarification on measuring liabilities at fair value when a quoted price in an active market is not available. In these circumstances, a valuation technique should be applied that uses either the quote of the liability when traded as an asset, the quoted prices for similar liabilities or similar liabilities when traded as assets, or another valuation technique consistent with existing fair value measurement guidance, such as an income approach or a market approach. The new guidance also clarifies that when estimating the fair value of a liability, a reporting entity is not required to include a separate input or adjustment to other inputs relating to the existence of a restriction that prevents the transfer of the liability. This guidance became effective beginning with the third quarter of the Company's 2010 fiscal year; however, the adoption of the new guidance did not have a material impact on the Company's financial position, results from operations or cash flows.

In June 2009, the FASB issued authoritative guidance to eliminate the exception to consolidate a qualifying special-purpose entity, change the approach to determining the primary beneficiary of a variable interest entity and require companies to more frequently re-assess whether they must consolidate variable interest entities. Under the new guidance, the primary beneficiary of a variable interest entity is identified qualitatively as the enterprise that has both (a) the power to direct the activities of a variable interest entity that most significantly impact the entity's economic performance, and (b) the obligation to absorb losses of the entity that could potentially be significant to the variable interest entity or the right to receive benefits from the entity that could potentially be significant to the variable interest entity. This guidance becomes effective for the Company's fiscal 2011 year-end and interim reporting periods thereafter. The Company does not expect this guidance to have a

material impact on its consolidated financial statements.

In June 2009, the FASB established the FASB ASC as the source of authoritative accounting principles recognized by the FASB to be applied in the preparation of financial statements in conformity with generally accepted accounting principles. The new guidance explicitly recognizes rules and interpretive releases of the SEC under federal securities laws as authoritative GAAP for SEC registrants. The new guidance became effective for our financial statements issued for the three and six month periods ending on September 30, 2009; however, the adoption of the new guidance in the second quarter of the Company's 2010 fiscal year did not have a material impact on the Company's financial position, results from operations or cash flows.

In May 2009, guidance was issued under the topic Subsequent Events related to the accounting for, and disclosure of, events that occur after the balance sheet date, but before the financial statements are issued or are available to be issued. Additionally, this guidance requires the Company to disclose the date through which subsequent events have been evaluated, as well as whether that date is the date the financial statements were issued or the date the financial statements were available to be issued. For the three and nine month periods ended December 31, 2009, the Company evaluated, for potential recognition and disclosure, events that occurred prior to the filing of the Company's Quarterly Report on Form 10-Q for the three and nine month periods ended December 31, 2009 on February 9, 2010.

The Financial Instruments Topic of the FASB ASC requires disclosures about the fair values of financial instruments at interim reporting periods in addition to annual financial statements. Effective April 1, 2009, the new guidance involves only enhanced disclosures and did not have any impact on the Company's financial position, results from operations or cash flows.

The Investments-Debt and Equity Securities topic of the FASB ASC modified the threshold a company must meet to avoid recognizing other-than-temporary impairments of debt securities purchased as investments. Effective April 1, 2009, the implementation of the new guidance did not have any impact on the Company's financial position, results from operations or cash flows.

The Derivatives and Hedging Topic of the FASB ASC requires a company with derivative instruments to disclose information to enable users of the financial statements to understand (i) how and why the company uses derivative instruments, (ii) how derivative instruments and related hedged items are accounted for, and (iii) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. Accordingly, the Derivatives and Hedging Topic requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. The Derivatives and Hedging Topic was effective for financial statements issued for fiscal years and interim periods beginning after November 15, 2008. The implementation of the Derivatives and Hedging guidance involved enhanced disclosures of derivative instruments and the Company's hedging activities and did not have any impact on the Company's financial position, results from operations or cash flows.

In September 2006, the FASB issued guidance on Fair Value Measurements and Disclosures to address inconsistencies in the definition and determination of fair value pursuant to GAAP. The guidance provides a single definition of fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements in an effort to increase comparability related to the recognition of market-based assets and liabilities and their impact on earnings. The Fair Value Measurements and Disclosures guidance was effective for the Company's interim financial statements issued after April 1, 2008. However, on November 14, 2007, the FASB deferred the effective date of the guidance for one year for non-financial assets and non-financial liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis. The implementation of the guidance, effective April 1, 2008, did not have a material effect on financial assets and liabilities included in the Company's consolidated financial statements as fair value is based on readily available market prices. Additionally, the implementation of the guidance did not have a material effect as it relates to non-financial assets and non-financial liabilities that are recognized or disclosed at fair value in the Company's financial statements on a non-recurring basis.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on the Company's consolidated financial position, results of operations or cash flows.

#### 2. Discontinued Operations and Sale of Certain of Assets

In October 2009, the Company sold certain assets related to the shampoo brands previously included in its Personal Care products segment to an unrelated third party. In accordance with the Discontinued Operations Topic of the ASC, the Company reclassified the related assets as held for sale in the consolidated balance sheets as of March 31, 2009 and reclassified the related operating results as discontinued in the consolidated financial statements and related notes for all periods presented. The Company recognized a gain of \$253,000 on a pre-tax basis and \$157,000 net of tax effects on the sale in the quarter ended December 31, 2009.

The following table presents the assets related to the discontinued operations as of March 31, 2009 (in thousands):

		March 31, 2009
Inventory	\$	1,038
Intangible assets	_	8,472
Total assets held for sale	\$	9,510

The following table summarizes the results of discontinued operations (in thousands):

	Three	Three Months Ended December 31,			Nine Months Ended Decem 31,			
	20	2009		2008 2		2009		2008
Components of Income								
Revenues	\$	651	\$	2,312	\$	4,998	\$	7,360
Income before income taxes		140		447		1,064		1,665

The total purchase price for the assets was \$9 million, subject to adjustments for inventory, as defined, with \$8 million received upon closing, and the remaining \$1 million to be paid on the first anniversary of the closing.

### 3. Accounts Receivable

Accounts receivable consist of the following (in thousands):

	ember 31, 2009	March 31 2009		
Trade accounts receivable	\$ 31,858	\$	37,521	
Other receivables	 1,522		1,081	
	33,380		38,602	
Less allowances for discounts, returns and				
uncollectible accounts	 (2,762)		(2,577)	
	\$ 30,618	\$	36,025	

#### 4. Inventories

Inventories consist of the following (in thousands):

	ember 31, 2009	March 31, 2009		
Packaging and raw materials	\$ 2,271	\$	1,955	
Finished goods	31,821		23,984	
	\$ 34,092	\$	25,939	

Inventories are shown net of allowances for obsolete and slow moving inventory of \$2.6 million and \$1.4 million at December 31, 2009 and March 31, 2009, respectively.

# 5. Property and Equipment

Property and equipment consist of the following (in thousands):

	December 31, 2009		arch 31, 2009
Machinery	\$ 1,621	\$	1,556
Computer equipment	1,326		1,021
Furniture and fixtures	239		239
Leasehold improvements	389		357
	3,575		3,173
Less accumulated depreciation	(2,278)		(1,806)
	\$ 1,297	\$	1,367

#### 6. Goodwill

A reconciliation of the activity affecting goodwill by operating segment is as follows (in thousands):

Balance – March 31, 2009	C	Over-the- Counter Healthcare		Household Cleaning								ersonal Care	Con	nsolidated
Goodwill	\$	229,627	\$	72,549	\$	2,751	\$	304,927						
Accumulated impairment losses		(125,527)	(	65,160)				(190,687)						
		104,100		7,389		2,751		114,240						
Net adjustments														
Balance – December 31, 2009														
Goodwill		229,627		72,549		2,751		304,927						
Accumulated impairment losses		(125,527)	(	65,160)				(190,687)						
	\$	104,100	\$	7,389	\$	2,751	\$	114,240						

At March 31, 2009, in conjunction with the annual test for goodwill impairment, the Company recorded an impairment charge aggregating \$190.7 million to adjust the carrying amounts of goodwill related to several reporting units within the Over-the-Counter Healthcare and Household Cleaning segments to their respective fair values. These charges were a consequence of the challenging economic environment experienced during our

fiscal year ended March 31, 2009, the dislocation of the debt and equity markets, and contracting consumer demand for the Company's product offerings. Although the impairment charges represent management's best estimate, the estimates and assumptions made in assessing the fair value of the Company's reporting units and the valuation of the underlying assets and liabilities are inherently subject to significant uncertainties. Consequently, changing rates of interest and inflation, declining sales or margins, increases in competition, changing consumer preferences, technical advances or reductions in advertising and promotion may require additional impairments in the future.

#### 7. Intangible Assets

A reconciliation of the activity affecting intangible assets is as follows (in thousands):

	 definite Lived demarks		Finite Lived ademarks		Non ompete reement		Totals
Carrying Amounts							
Balance – March 31, 2009	\$ 500,176	\$	106,773	\$	158	\$	607,107
Reclassifications	(45,605)		45,605				
			<u> </u>	_			
Balance – December 31, 2009	\$ 454,571	\$	152,378	\$	158	\$	607,107
	 - ,-	<u> </u>		<del>-</del>		Ė	
Accumulated Amortization							
Balance – March 31, 2009	\$ 	\$	37,828	\$	142	\$	37,970
Additions			7,293		16		7,309
							,
Balance – December 31, 2009	\$ 	\$	45,121	\$	158	\$	45,279
						_	

At March 31, 2009, in a manner similar to goodwill, the Company completed a test for impairment of its intangible assets. Accordingly, the Company recorded an impairment charge aggregating \$58.9 million during the three month period ended March 31, 2009 to the Over-the-Counter Healthcare and Household Cleaning segments as facts and circumstances indicated that the carrying values of the assets exceeded their fair values and may not be recoverable.

The economic events experienced during the fiscal year ended March 31, 2009, as well as the Company's plans and projections for its brands indicated that several of such brands can no longer support indefinite useful lives. Each of these brands incurred an impairment charge during the three month period ended March 31, 2009 and has been adversely affected by increased competition and the macroeconomic environment in the United States. Consequently, at April 1, 2009, management reclassified \$45.6 million of previously indefinite-lived intangibles to intangibles with definite lives. Management estimates the remaining useful lives of these intangibles to be 20 years.

The fair values and the annual amortization charges of the reclassified intangibles are as follows (in thousands):

Intangible	a Ma	r Value ns of rch 31, 2009	nnual rtization
Household Trademarks	\$	34,888	\$ 1,745
OTC Healthcare Trademark		10,717	536
	\$	45,605	\$ 2,281
	-12-		

At December 31, 2009, all finite-lived intangible assets are expected to be amortized over a period of 3 to 30 years as follows (in thousands):

# **Year Ending December**

_
9,725
9,337
8,834
8,127
6,312
4,922
7,257
,

# 8. Other Accrued Liabilities

Other accrued liabilities consist of the following (in thousands):

	December 31, 2009		•	
Accrued marketing costs	\$	3,736	\$	3,519
Accrued payroll		3,807		750
Accrued commissions		315		312
Accrued income taxes		-		679
Accrued professional fees		2,955		1,906
Interest rate swap obligation		794		2,152
Severance		1,646		-
Other		5		89
	\$	13,258	\$	9,407

During the second quarter of fiscal 2010, the Company completed a staff reduction program to eliminate approximately 10% of its workforce. The accrued severance balance as of December 31, 2009 is related to this reduction in workforce and consists primarily of the remaining payments of salaries, bonuses and other benefits for separated employees.

The Company has reclassified the interest rate swap liability of \$2.2 million as of March 31, 2009 from accounts payable to accrued liabilities.

# 9. Long-Term Debt

Long-term debt consists of the following (in thousands):

Tong term debt consists of the following (in thousands).	December 31, 2009	March 31, 2009
Senior secured term loan facility ("Tranche B Term Loan Facility") that bears interest at the Company's option at either the prime rate plus a margin of 1.25% or LIBOR plus a margin of 2.25%. At December 31, 2009, the interest rate on the Tranche B Term Loan Facility was 2.48%. The interest rate is adjusted either monthly or quarterly at the Company's option. Principal payments of \$887,500 plus accrued interest are payable quarterly. Current amounts outstanding under the Tranche B Term Loan Facility mature on April 6, 2011 and are collateralized by substantially all of the Company's assets.	\$ 193,337	\$ 252,337
Senior Subordinated Notes that bear interest at 9.25% which is payable on April 15 <sup>th</sup> and October 15 <sup>th</sup> of each year. The Senior Subordinated Notes mature on April 15, 2012; however, the Company may redeem some or all of the Senior Subordinated Notes at redemption prices set forth in the indenture governing the Senior Subordinated Notes. The Senior Subordinated Notes are unconditionally guaranteed by Prestige Brands Holdings, Inc., and its domestic wholly-owned subsidiaries other than Prestige Brands, Inc., the issuer. Each of these guarantees is joint and several. There are no significant restrictions on the ability of any of the guarantors to obtain funds from their subsidiaries.	126,000	126,000
	319,337	378,337
Current portion of long-term debt	(3,550)	(3,550)
	\$ 315,787	\$ 374,787

The Tranche B Term Loan Facility contains various financial covenants, including provisions that require the Company to maintain certain leverage ratios, interest coverage ratios and fixed charge coverage ratios. The Tranche B Term Loan Facility and the Senior Subordinated Notes also contain provisions that restrict the Company from undertaking certain specified corporate actions, such as asset dispositions, acquisitions, dividend payments, repurchase of common shares outstanding, changes of control, incurrence of indebtedness, creation of liens, making of loans and transactions with affiliates. Additionally, the Tranche B Term Loan Facility and the Senior Subordinated Notes contain cross-default provisions whereby a default pursuant to the terms and conditions of either indebtedness will cause a default on the remaining indebtedness.

Future principal payments required in accordance with the terms of the Tranche B Term Loan Facility and the Senior Subordinated Notes are as follows (in thousands):

#### **Year Ending December**

J1	
2010	\$ 3,5
2011	189,7
2012	126,0
	<u>\$ 319,3</u>

#### 10. Fair Value Measurements

As deemed appropriate, the Company uses derivative financial instruments to mitigate the impact of changing interest rates associated with its long-term debt obligations. At December 31, 2009, the outstanding obligation

under the Company's variable rate Tranche B Term Loan Facility was \$193.3 million. Although the Company does not enter into derivative financial instruments for trading purposes, all of the Company's derivatives are over-the-counter instruments with liquid markets. The notional, or contractual, amount of the Company's derivative financial instruments is used to measure the amount of interest to be paid or received and does not represent an actual liability. The Company is accounting for the interest rate cap and swap agreements as cash flow hedges.

The Company entered into an interest rate swap agreement, effective March 26, 2008, in the notional amount of \$175.0 million that decreased to \$125.0 million at March 26, 2009. The Company has agreed to pay a fixed rate of 2.88% while receiving a variable rate based on LIBOR. The agreement terminates on March 26, 2010.

As more fully described in Note 1, the Company adopted fair value accounting for all financial instruments. The Fair Value Measurements and Disclosures Topic of the FASB ASC requires fair value to be determined based on the exchange price that would be received for an asset or paid to transfer a liability in the principal or most advantageous market assuming an orderly transaction between market participants. The Fair Value Measurements and Disclosures Topic established market (observable inputs) as the preferred source of fair value to be followed by the Company's assumptions of fair value based on hypothetical transactions (unobservable inputs) in the absence of observable market inputs.

Based upon the above, the following fair value hierarchy was created:

Level  $^1$  Quoted market prices for identical instruments in active markets,

Level 2 Quoted prices for similar instruments in active markets, as well as quoted prices for identical or similar instruments in markets that are not —considered active, and

Level 3 Unobservable inputs developed by the Company using estimates and assumptions reflective of those that would be utilized by a market –participant.

Fair Value Measurements at December 31, 2009

Quantitative disclosures about the fair value of the Company's derivative hedging instruments are as follows (in thousands):

Description	Dec	ember 31, 2009	Quoted Prices in Active Markets for Identical Assets (Level 1)	9	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Interest Rate Swap Liability	\$	794	\$ -	- \$	794	\$
			Fair Value Ouoted Price		urements at M	arch 31, 2009
			in Active		Significant	
			Markets for		Other	Significant
			Identical	(	Observable	Unobservable
	M	arch 31,	Assets		Inputs	Inputs
Description		2009	(Level 1)	_	(Level 2)	(Level 3)
Interest Rate Swap Liability	\$	2,152	\$ -	- \$	2,152	\$

A summary of the fair value of the Company's derivative instruments, their impact on the consolidated statements of operations and comprehensive income and the amounts reclassified from other comprehensive income is as follows (in thousands):

				For the Three M	Months Ended Decen	nber 31, 2009
	1	December 31, 2009		Income Statement Account	Amount Income	Amount Gains
Cash Flow Hedging Instruments	Balance Sheet Location	Notional Amount	Fair Value Asset/ (Liability)	Gains/ Losses Charged	(Expense) Recognized In Income	(Losses) Recognized In OCI
Interest Rate Swap	Other Accrued Liabilities	\$ 125,000	\$ (794	Interest ) Expense	\$ (830)	\$ 778
		D 1 24 2000		Income Statement	Ionths Ended Decem	Amount
Cash Flow Hedging Instruments	Balance Sheet Location	December 31, 2009  Notional  Amount	Fair Value Asset/ (Liability)	Account Gains/ Losses Charged	Income (Expense) Recognized In Income	Gains (Losses) Recognized In OCI
Interest Rate Swap	Other Accrued Liabilities	\$ 125,000	\$ (794	Interest ) Expense	\$ (2,090)	\$ 1,358
	1	December 31, 2008		For the Three M Income Statement Account	Months Ended Decen  Amount Income	Amount Gains
Cash Flow Hedging Instruments	Balance Sheet Location	Notional Amount	Fair Value Asset/ (Liability)	Gains/ Losses Charged	(Expense) Recognized In Income	(Losses) Recognized In OCI
Interest Rate Swap	Prepaid expenses	\$ 175,000	\$ (2,680	Interest ) Income	\$ 247	\$ (3,455
	1	December 31, 2008		For the Nine M Income Statement Account	Ionths Ended Decem  Amount Income	ber 31, 2008  Amount Gains
Cash Flow Hedging Instruments	Balance Sheet Location	Notional Amount	Fair Value Asset/ (Liability)	Gains/ Losses Charged	(Expense) Recognized In Income	(Losses) Recognized In OCI
	Prepaid			Interest		

The Company recorded interest expense of \$830,000 and interest income of \$247,000 during the three month periods ended December 31, 2009 and 2008, respectively, in connection with this interest rate swap agreement. The Company recorded interest expense of \$2.1 million and interest income of \$111,000 during the nine month periods ended December 31, 2009 and 2008, respectively, in connection with this interest rate swap agreement. Assuming that the LIBOR rate does not fluctuate subsequent to December 31, 2009, the Company estimates that

\$

(2,680) Income

\$

111 \$

(1,153)

175,000

\$

expenses

Interest Rate Swap

it will recognize approximately \$822,000 in additional interest expense during the remaining three months of its fiscal year ending March 31, 2010.

At December 31, 2009 and March 31, 2009, the fair values of the interest rate swap liability were \$794,000 and \$2.2 million, respectively. Such amounts were included in other accrued liabilities. The determination of fair value is based on closing prices for similar instruments traded in liquid over-the-counter markets. The changes in the fair value of this interest rate swap are recorded in Accumulated Other Comprehensive Income in the balance sheet due to its designation as a cash flow hedge.

For certain of our financial instruments, including cash, accounts receivable, accounts payable and other current liabilities, the carrying amounts approximate their respective fair values due to the relatively short maturity of these amounts.

At December 31, 2009 and March 31, 2009, the carrying value of the Tranche B Term Loan Facility was \$193.3 and \$252.3 million, respectively. The terms of the facility provide that the interest rate is adjusted, at the Company's option, on either a monthly or quarterly basis, to the prime rate plus a margin of 1.25% or LIBOR plus a margin of 2.25%. The market value of the Company's Tranche B Term Loan Facility was approximately \$189.4 million and \$244.8 million at December 31, 2009 and March 31, 2009 and March 31, 2009, the carrying value of the Company's 9.25% Senior Subordinated Notes was \$126.0 million. The market value of these notes was approximately \$127.3 million and \$119.7 million at December 31, 2009 and March 31, 2009, respectively. The market values of the notes have been determined from market transactions in the Company's debt securities.

### 11. Stockholders' Equity

The Company is authorized to issue 250.0 million shares of common stock, \$0.01 par value per share, and 5.0 million shares of preferred stock, \$0.01 par value per share. The Board of Directors may direct the issuance of the undesignated preferred stock in one or more series and determine preferences, privileges and restrictions thereof.

Each share of common stock has the right to one vote on all matters submitted to a vote of stockholders. The holders of common stock are also entitled to receive dividends whenever funds are legally available and when declared by the Board of Directors, subject to prior rights of holders of all classes of stock outstanding having priority rights as to dividends. No dividends have been declared or paid on the Company's common stock through December 31, 2009.

During the year ended March 31, 2009, the Company repurchased 65,000 shares of restricted common stock from former employees pursuant to the provisions of the various employee stock purchase agreements. All of such shares have been recorded as treasury stock. There were no share repurchases during the three or nine month periods ended December 31, 2009.

# 12. Earnings Per Share

The following table sets forth the computation of basic and diluted earnings per share (in thousands, except per share data):

	Three Months Ended December 31		Nin		s Ended Decembe 31		
		2009	2008		2009		2008
Numerator		·					
Income from continuing operations	\$	10,336	\$ 7,740	\$	28,010	\$	23,287
Income from discontinued operations and gain on sale of discontinued operations		244	278		818		1,034
Net income	\$	10,580	\$ 8,018	\$	28,828	\$	24,321
Denominator							
Denominator for basic earnings per share – weighted average shares		50,030	49,960		50,008		49,921
Dilutive effect of unvested restricted common stock (including restricted stock units), options and stock appreciation rights issued to employees and directors		44	80		70		117
Denominator for diluted earnings per share		50,074	50,040		50,078		50,038
Denominator for anacca carmings per share		30,074	30,040	_	30,070		50,050
Earnings per Common Share:							
Basic earnings per share from continuing operations	\$	0.21	\$ 0.15	\$	0.56	\$	0.47
Basic earnings per share from discontinued operations and gain on sale of discontinued operations			0.01		0.02		0.02
Basic net earnings per share	\$	0.21	\$ 0.16	\$	0.58	\$	0.49
Diluted earnings per share from continuing operations	\$	0.21	\$ 0.15	\$	0.56	\$	0.47
Diluted earnings per share from discontinued operations and gain on sale of discontinued operations			0.01		0.02		0.02
Diluted net earnings per share	\$	0.21	\$ 0.16	\$	0.58	\$	0.49

At December 31, 2009, 212,202 shares of restricted stock granted to employees, including restricted stock units, subject only to time vesting, were unvested and excluded from the calculation of basic earnings per share; however, such shares were included in the calculation of diluted earnings per share. Additionally, 101,802 shares of restricted stock granted to employees have been excluded from the calculation of both basic and diluted earnings per share because vesting of such shares is subject to contingencies that were not met as of December 31, 2009. Lastly, at December 31, 2009, there were options to purchase 1,391,172 shares of common stock outstanding that were not included in the computation of diluted earnings per share because their exercise price was greater than the average market price of the common stock, and therefore, their inclusion would be antidilutive.

At December 31, 2008, 195,000 shares of restricted stock granted to employees, subject only to time-vesting, were unvested and excluded from the calculation of basic earnings per share; however, such shares were included

in the calculation of diluted earnings per share. Additionally, 437,000 shares of restricted stock granted to employees, as well as 15,000 stock appreciation rights have been excluded from the calculation of both basic and diluted earnings per share because vesting of such shares is subject to contingencies that were not met as of December 31, 2008. Lastly, at December 31, 2008, there were options to purchase 663,000 shares of common stock outstanding that were not included in the computation of diluted earnings because their exercise price was greater than the average market price of the common stock, and therefore, their inclusion would be antidilutive.

#### 13. Comprehensive Income

The following table describes the components of comprehensive income for each of the three and nine month periods ended December 31, 2009 and 2008 (in thousands):

	Thre	ee Months E	Ended 1	December
		2009		2008
Components of Comprehensive Income				,
t income	\$	10,580	\$	8,018
11 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1				
realized gain (loss) on interest rate caps, net of income tax of \$296		400		(2.142)
009) and \$(1,313) (2008)	_	482	_	(2,142)
omprehensive Income	\$	11,062	\$	5,876
F	<u> </u>			
		e Months E		December
		3	nded 1	
				December 2008
omponents of Comprehensive Income		3		
omponents of Comprehensive Income et income	Nin-	2009	1	2008
Components of Comprehensive Income  Met income  Amortization of interest rate caps reclassified into earnings, net of income	Nin-	2009	1	2008
omponents of Comprehensive Income fet income mortization of interest rate caps reclassified into earnings, net of income x of \$32 (2008)	Nin-	2009	1	24,321
omponents of Comprehensive Income et income mortization of interest rate caps reclassified into earnings, net of income to of \$32 (2008)  mealized gain (loss) on interest rate caps, net of income tax of \$516	Nin-	2009 28,828 	1	<b>2008</b> 24,321 53
Components of Comprehensive Income  Tet income  Tet income  Temortization of interest rate caps reclassified into earnings, net of income ax of \$32 (2008)  Temperature of the comprehensive income tax of \$516	Nin-	2009	1	24,321
Components of Comprehensive Income  Net income  Amortization of interest rate caps reclassified into earnings, net of income tax of \$32 (2008)  Unrealized gain (loss) on interest rate caps, net of income tax of \$516 (2009) and \$(438) (2008)  Comprehensive Income	Nin-	2009 28,828 	1	<b>2008</b> 24,321 53

#### 14. Share-Based Compensation

In connection with the Company's initial public offering, the Board of Directors adopted the 2005 Long-Term Equity Incentive Plan ("Plan") which provides for the grant, to a maximum of 5.0 million shares, of restricted stock, stock options, restricted stock units, deferred stock units and other equity-based awards. Directors, officers and other employees of the Company and its subsidiaries, as well as others performing services for the Company, are eligible for grants under the Plan. The Company believes that such awards better align the interests of its employees with those of its stockholders.

During the nine month period ended December 31, 2009, net compensation costs charged against income and the related income tax benefit recognized were \$1.7 million and \$630,000, respectively. During the nine month

period ended December 31, 2008, net compensation costs charged against income, and the related tax benefits recognized were \$2.2 million and \$852,000, respectively.

#### **Restricted Shares**

Restricted shares granted to employees under the Plan generally vest in 3 to 5 years, contingent on attainment by the Company of revenue and earnings before income taxes, depreciation and amortization growth targets, or the attainment of certain time vesting thresholds. Certain restricted share awards provide for automatic accelerated vesting if there is a change of control, as defined in the plan or document pursuant to which the awards were made. The fair value of nonvested restricted shares is determined as the closing price of the Company's common stock on the day preceding the grant date. The weighted-average fair values of restricted shares granted during the nine month periods ended December 31, 2009 and 2008 were \$7.09 and \$10.85, respectively.

A summary of the Company's restricted shares granted under the Plan is presented below:

Restricted Shares	Shares (in thousands)	Weighted- Average Grant-Date Fair Value
Nonvested at March 31, 2009	342.4	\$ 11.31
Granted	171.6	7.09
Vested	(47.8)	10.97
Forfeited	(152.2)	11.54
Nonvested at December 31, 2009	314.0	8.94
Nonvested at March 31, 2008	484.7	11.78
Granted	303.5	10.85
Vested	(29.9)	10.88
Forfeited	(138.1)	12.24
Nonvested at December 31, 2008	620.2	11.26

#### **Options**

The Plan provides that the exercise price of the option granted shall be no less than the fair market value of the Company's common stock on the date the option is granted. Options granted have a term of no greater than 10 years from the date of grant and vest in accordance with a schedule determined at the time the option is granted, generally 3 to 5 years. Certain option awards provide for automatic accelerated vesting if there is a change in control.

The fair value of each option award is estimated on the date of grant using the Black-Scholes Option Pricing Model ("Black-Scholes Model") that uses the assumptions noted in the following table. Expected volatilities are based on the historical volatility of the Company's common stock and other factors, including the historical volatilities of comparable companies. The Company uses both historical and current data to estimate option exercise and employee termination behaviors. Employees that are expected to exhibit similar exercise or termination behaviors are grouped together for the purposes of valuation. The expected terms of the options granted are derived from management's estimates and consideration of information derived from the public filings of companies similar to the Company and represent the period of time that options granted are expected to be outstanding. The risk-free rate represents the yield on U.S. Treasury bonds with a maturity equal to the expected term of the granted option. The weighted-average grant-date fair value of the options granted during the nine month period ended December 31, 2009 and 2008 was \$3.64 and \$5.04, respectively.

#### Nine month period Ended December 31

		_		
	2009	2008		
Expected volatility	45.6%	43.3%		
Expected dividends				
Expected term in years	7.0	6.0		
Risk-free rate	2.8%	3.2%		

A summary of option activity under the Plan is as follows:

Options	Shares (in thousands)	Weighted- Average Exercise Price	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Outstanding at March 31, 2008	253.5	\$ 12.86	9.2	\$
Granted	413.3	10.91	9.4	
Exercised				
Forfeited or expired	(4.1)	11.83	9.1	
Outstanding at December 31, 2008	662.7	11.65	9.0	
Outstanding at March 31, 2009	662.6	11.65	8.8	
Granted	1,125.0	7.16	9.7	
Exercised				
Forfeited or expired	(142.6)	11.26	1.2	
Outstanding at December 31, 2009	1,645.0	8.61	9.1	
Exercisable at December 31, 2009	304.7	11.98	7.9	

#### Stock Appreciation Rights ("SARs")

In July 2006, the Board of Directors granted SARs to a group of selected executives; however, no SARs have been granted since that date. The terms of the SARs provided that on the vesting date, the executive would receive for each SAR awarded to an executive the excess of the market price of the Company's common stock on the vesting date over the market price of the Company's common stock on the date the award was granted. The Board of Directors, in its sole discretion, may settle the Company's obligation to the executive in shares of the Company's common stock, cash, other securities of the Company or any combination thereof.

The Plan provides that the issuance price of a SAR shall be no less than the market price of the Company's common stock on the date the SAR is granted. SARs may be granted with a term of no greater than 10 years from the date of grant and will vest in accordance with a schedule determined at the time the SAR is granted, generally 3 to 5 years. The weighted-average grant date fair value of the SARs granted was \$3.68. The fair value of each SAR award was estimated on the date of grant using the Black-Scholes Model. The SARs expired on March 31, 2009; and no compensation was paid because the grant-date market price of the Company's common stock exceeded the market value of the Company's common stock on the measurement date.

SARs	Shares (in thousands)	Grant Date Stock Price	Weighted- Average Remaining Contractual Term	Aggregate Intrinsic Value (in thousands)
Outstanding at March 31, 2008	16.1	\$ 9.97	1.00	\$
Granted				
Forfeited or expired	(1.2)	9.97	0.25	
Outstanding at December 31, 2008	14.9	9.97	0.25	

At December 31, 2009, there were \$5.5 million of unrecognized compensation costs related to nonvested share-based compensation arrangements under the Plan based on management's estimate of the shares that will ultimately vest. The Company expects to recognize such costs over the next 4 years. However, certain of the restricted shares vest upon the attainment of Company performance goals and if such goals are not met, no compensation costs would ultimately be recognized and any previously recognized compensation cost would be reversed. The total fair value of shares vested during the nine months ended December 31, 2009 and 2008 was \$525,000 and \$300,000, respectively. There were no options exercised during either of the nine month periods ended December 31, 2009 and 2008; hence, there were no tax benefits realized during these periods. At December 31, 2009, there were 2.9 million shares available for issuance under the Plan.

#### 15. Income Taxes

Income taxes are recorded in the Company's quarterly financial statements based on the Company's estimated annual effective income tax rate subject to adjustments for discrete events should they occur. The effective tax rates used in the calculation of income taxes were 42.92% and 39.84%, respectively, for the three and nine month period ended December 31, 2009. The effective tax rate used in the calculation of income taxes was 37.9% for the three and nine month period ended December 31, 2008. The income tax expense for the three and nine month period ended December 31, 2009 includes a discrete adjustment to the Company's deferred tax liabilities of \$930,000 for expected future increases in the effective state income tax rate.

At December 31, 2009, Medtech Products Inc., a wholly-owned subsidiary of the Company, had a net operating loss carryforward of approximately \$2 million which may be used to offset future taxable income of the consolidated group and which begins to expire in 2020. The net operating loss carryforward is subject to an annual limitation as to usage pursuant to Internal Revenue Code Section 382 of approximately \$240,000.

Uncertain tax liability activity is as follows:

	20	09	2008
(In thousands)			
Balance - March 31	\$	225 \$	
Adjustments based on tax positions related to			
the current year		100	
Balance - December 31	\$	325 \$	

The Company recognizes interest and penalties related to uncertain tax positions as a component of income tax expense. The Company does not anticipate any significant events or circumstances that would cause a change to these uncertainties during the ensuing year.

#### 16. Commitments and Contingencies

#### Securities Class Action Litigation

The Company and certain of its officers and directors were defendants in a consolidated securities class action lawsuit filed in the United States District Court for the Southern District of New York (the "Consolidated Action"). Plaintiffs purported to represent a class of stockholders of the Company who purchased shares of the Company's common stock from February 9, 2005 through November 15, 2005 (the "Class Period"). Plaintiffs also named as defendants the underwriters in the Company's initial public offering and a private equity fund that was a selling stockholder in the offering. On September 4, 2007, the Court issued an Order certifying a class consisting of all persons who purchased the Company's common stock pursuant, or traceable to, the Company's initial public offering during the Class Period and were damaged thereby. After having given notice to class members, the defendants and the lead plaintiffs have reached an agreement in principle to settle the Consolidated Action. On December 4, 2009, the settlement proposed by the defendants and the lead plaintiffs received final approval from the Court. Insurance covered the costs of all payments to the plaintiffs and their counsel. As a result, the Consolidated Action, and all claims made therein against us, our officers and directors and the other defendants in the action were dismissed with prejudice.

#### **DenTek Litigation**

In April 2007, the Company filed a lawsuit in the United States District Court in the Southern District of New York against DenTek Oral Care, Inc. ("DenTek") alleging (i) infringement of intellectual property associated with *The Doctor's® NightGuard™* Dental Protector which is used for the protection of teeth from nighttime teeth grinding; and (ii) the violation of unfair competition and consumer protection laws. On October 4, 2007, the Company filed a Second Amended Complaint in which it named Kelly M. Kaplan, Raymond Duane and C.D.S. Associates, Inc. ("CDS") as additional defendants in this action and added other claims to the previously filed complaint. Kaplan and Duane were formerly employed by the Company, and CDS is a corporation controlled by Duane through which Duane provided services to the Company. In the Second Amended Complaint, the Company has asserted claims for patent, trademark and copyright infringement, unfair competition, unjust enrichment, violation of New York's Consumer Protection Act, breach of contract, tortious interference with contractual and business relations, civil conspiracy and trade secret misappropriation. On October 19, 2007, the Company filed a motion for preliminary injunction, asking the Court to enjoin the defendants from (i) continuing to improperly use the Company's trade secrets; (ii) continuing to breach any contractual agreements with the Company; and (iii) marketing and selling any dental protector products or other products in which Duane or Kaplan has had any involvement or provided any assistance to DenTek. A hearing date for the motion for preliminary injunction has not yet been set by the Court.

On September 30, 2008, after considering the defendants' motions to dismiss, the Company's responses (including a motion to strike the motions to dismiss) and the Magistrate's Report and Recommendations, the Court granted in part and denied in part the defendants' Motions to Dismiss, with the following claims being dismissed without prejudice: (1) breach of the Proprietary Information and Inventions Agreement ("PIIA") against Duane; (2) breach of the PIIA against Kaplan; (3) tortious interference with contractual relations against DenTek; (4) tortious interference with contractual relations against Duane; and (5) tortious interference with advantageous business relationship/economic advantage against all defendants. The Court denied the Company's Motions to Strike the Motions to Dismiss filed by DenTek and CDS. The following claims included in the Company's Second Amended Complaint remain in the action: (1) patent, trademark and copyright infringement against DenTek; (2) unjust enrichment against DenTek; (3) violation of a New York consumer protection statute against DenTek; (4) breach of the consulting agreement against Duane; (5) breach of the PIIA against CDS; (6) breach of the release against Kaplan and Duane; and (7) trade secret misappropriation against DenTek, Kaplan, Duane and CDS.

In October 2008, DenTek, Kaplan, Duane and CDS filed Answers to the Second Amended Complaint. In their Answers, each of DenTek, Duane and CDS has asserted counterclaims against the Company. DenTek's counterclaims allege false advertising, violation of New York consumer protection statutes and unfair competition relating to *The Doctor*'s® *NightGuard*<sup>TM</sup> *Classic*<sup>TM</sup> dental protector. Duane's counterclaim is a contractual indemnity claim seeking to recover attorneys' fees pursuant to the release between Duane and Dental Concepts

LLC ("Dental Concepts"), a predecessor-in-interest to Medtech Products Inc., plaintiff in the DenTek litigation and another wholly-owned subsidiary of Prestige Brands Holdings, Inc. CDS' counterclaim alleges a breach of the consulting agreement between CDS and Dental Concepts.

In November 2008, in response to the counterclaims filed against the Company by DenTek, Duane and CDS, the Company filed a Motion to Dismiss and Strike the counterclaims made by DenTek, which motion is currently pending before the Court. In addition, in November 2008, the Company filed an Answer to the counterclaims asserted by Duane and CDS.

On March 24, 2009, Duane submitted a petition for a Chapter 7 bankruptcy with the United States Bankruptcy Court for the District of Nevada (the "Nevada Bankruptcy Court") which automatically stayed the DenTek litigation in which Duane is a defendant. On July 21, 2009, the Nevada Bankruptcy Court granted the Company's motion for relief from automatic stay with respect to the DenTek litigation against DenTek, Kaplan, Duane and CDS. Accordingly, the DenTek litigation has resumed although the Nevada Bankruptcy Court retains exclusive jurisdiction over any damage claims and other issues which may affect Duane's bankruptcy proceeding, except for orders of injunctive relief that may be issued in the DenTek litigation.

On November 5, 2009, the Court issued an Opinion and Order construing one of the claims of the Company's U.S. Patent No. 6,830,051, which forms the basis for the patent infringement claims in the DenTek litigation. The Company believes the Opinion and Order issued by the Court is favorable to the Company's patent infringement claim against DenTek.

On January 15, 2010, the Company and DenTek reached a tentative settlement agreement in principle to resolve the pending litigation between the Company and DenTek during a settlement conference before the Court. The settlement agreement remains subject to the negotiation and execution of a written settlement agreement acceptable to the Company and DenTek. As of the date of this Quarterly Report, a final settlement agreement was not yet executed by the parties. There can be no assurance that the Company and DenTek will ultimately execute a final settlement agreement and that the litigation will be resolved. In the event that a final settlement agreement is not executed or the litigation is not otherwise resolved, the litigation will resume.

The Company's management believes that the counterclaims asserted by DenTek, Duane and CDS are legally deficient and that it has meritorious defenses to the counterclaims. In the event the settlement is not consummated and the litigation resumes, the Company intends to vigorously defend against the counterclaims; however, the Company cannot, at this time, reasonably estimate the potential range of loss, if any. The settlement agreement has no impact on the litigation pending between the Company and each of Duane, CDS and Kaplan.

In addition to the matters described above, the Company is involved from time to time in other routine legal matters and other claims incidental to its business. The Company reviews outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). The Company believes the resolution of routine matters and other incidental claims, taking into account reserves and insurance, will not have a material adverse effect on its business, financial condition or results from operations.

#### Lease Commitments

The Company has operating leases for office facilities and equipment in New York and Wyoming, which expire at various dates through 2014.

The following summarizes future minimum lease payments for the Company's operating leases (in thousands):

	Fac	ilities	Equipment	Total
Year Ending December				
31				
2010	\$	698	\$ 83	\$ 781
2011		555	79	634
2012		573	45	618
2013		591	27	618
2014		199		199
	\$	2,616	\$ 234	\$ 2,850

Rent expense for the three and nine month periods ended December 31, 2009 was \$206,000 and \$554,000, respectively, while rent expense for the three and nine month periods ended December 31, 2008 was \$155,000 and \$461,000, respectively.

#### **Purchase Commitments**

The Company has entered into a 10 year supply agreement for the exclusive manufacture of a portion of one of its household cleaning products. Although the Company is committed under the supply agreement to pay the minimum amounts set forth in the table below, the Company estimates that it will purchase in excess of \$270.0 million of the product during the term of the agreement.

# (In thousands)

#### **Year Ending December**

31	
2010	\$ 10,743
2011	7,541
2012	1,181
2013	1,137
2014	1,094
Thereafter	3,942
	\$ 25,638

#### 17. Concentrations of Risk

The Company's sales are concentrated in the areas of over-the-counter healthcare, household cleaning and personal care products. The Company sells its products to mass merchandisers, food and drug accounts, and dollar and club stores. During the three and nine month periods ended December 31, 2009, approximately 62.3% and 62.8%, respectively, of the Company's total sales were derived from its four major brands, while during the three and nine month periods ended December 31, 2008 approximately 61.1% and 58.9%, respectively, of the Company's total sales were derived from its four major brands. During the three and nine month periods ended December 31, 2009, approximately 24.9% and 25.0%, respectively, of the Company's sales were made to one customer, while during the three and nine month periods ended December 31, 2008, 26.6% and 25.9%, respectively, of sales were to this customer. At December 31, 2009, approximately 22.9% of accounts receivable were owed by the same customer.

The Company manages product distribution in the continental United States through a main distribution center in St. Louis, Missouri. A serious disruption, such as a flood or fire, to the main distribution center could damage the Company's inventories and could materially impair the Company's ability to distribute its products to customers in a timely manner or at a reasonable cost. The Company could incur significantly higher costs and experience longer lead times associated with the distribution of its products to its customers during the time that it takes the

Company to reopen or replace its distribution center. As a result, any such disruption could have a material adverse affect on the Company's sales and profitability.

The Company has relationships with over 36 third-party manufacturers. Of those, the top 10 manufacturers produced items that accounted for approximately 79% of the Company's gross sales for the nine months ended December 31, 2009 compared to 75% during the nine months ended December 31, 2008. The Company did not have long-term contracts with manufacturers of product of approximately 20% of our gross sales for the nine months ended December 31, 2009 compared to 20% during the nine months ended December 31, 2008. The lack of manufacturing agreements for these products exposes the Company to the risk that a manufacturer could stop producing the Company's products at any time for any reason, increase the cost we are charged for our products, or fail to provide the Company with the level of products the Company needs to meet its customers' demands. Should one or more of our manufacturers stop producing product on our behalf or increase our costs in excess of our ability to increase our sales price, it could have a material adverse effect on our business, financial condition and results from operations.

### 18. Business Segments

Segment information has been prepared in accordance with the Segment Topic of the FASB ASC. The Company's operating and reportable segments consist of (i) Over-the-Counter Healthcare, (ii) Household Cleaning and (iii) Personal Care.

There were no inter-segment sales or transfers during any of the periods presented. The Company evaluates the performance of its operating segments and allocates resources to them based primarily on contribution margin.

The table below summarizes information about the Company's operating and reportable segments.

		Th	ree Mo	d Dec	ember 31, 20	09		
		Over-the- Counter Healthcare				Personal Care	Consolidated	
(In thousands)	_		_		_		_	
Net sales	\$	46,160	\$	26,828	\$	2,009	\$	74,997
Other revenues		9		437	_	5		451
Total revenues		46,169		27,265		2,014		75,448
Cost of sales		16,919		17,481		1,241		35,641
Cost of suits		10,313		17,401	_	1,271		55,041
Gross profit		29,250		9,784		773		39,807
Advertising and promotion		5,146		877		76		6,099
Contribution margin	\$	24,104	\$	8,907	\$	697		33,708
Other operating expenses								10,007
Operating income								23,701
Other expense								5,558
Provision for income taxes								7,807
Income from continuing operations								10,336
Income from discontinued operations, net of income tax								87
Gain on sale of discontinued operations, net of income tax								157
Net income							\$	10,580

		Nine Months Ended December 31, 2009							
		Over-the- Counter Healthcare			Personal Care		Cor	nsolidated	
(In thousands)									
Net sales	\$	137,800	\$	82,271	\$	9,059	\$	229,130	
Other revenues		29		1,454		28		1,511	
Table 1		127.020		00.705		0.007		220 641	
Total revenues		137,829		83,725		9,087		230,641	
Cost of sales		49,664		53,765		5,241		108,670	
Gross profit		88,165		29,960		3,846		121,971	
Advertising and promotion		19,264		5,080		301		24,645	
Contribution margin	\$	68,901	\$	24,880	\$	3,545		97,326	
Other operating expenses								33,869	
Operating income								63,457	
Other expense								16,853	
Provision for income taxes								18,594	
Income from continuing operations								28,010	
Income from discontinued operations, net of income tax								661	
								157	
Gain on sale of discontinued operations, net of income tax								157	
Net income							\$	28,828	

		Three Months Ended December 31, 2008							
		Over-the- Counter ealthcare	Household Cleaning		Personal Care		Consolidated		
(In thousands)									
Net sales	\$	47,526	\$	27,586	\$	2,233	\$	77,345	
Other revenues		69		552				621	
Total revenues		47,595		28,138		2,233		77,966	
Cost of sales		16,892		18,253		1,335		36,480	
Gross profit		30,703		9,885		898		41,486	
Advertising and promotion		9,459		1,794		96		11,349	
Contribution margin	\$	21,244	\$	8,091	\$	802		30,137	
Other operating expenses								10,622	
Operating income								19,515	
Other expense								7,051	
Provision for income taxes								4,724	
Income from continuing operations								7,740	
Income from discontinued operations, net of income tax								278	
Net income							\$	8,018	

		Nine Months Ended December 31, 2008							
		Over-the- Counter Healthcare		Household Cleaning		Personal Care		ısolidated	
(In thousands)									
Net sales	\$	137,090	\$	87,472	\$	8,020	\$	232,582	
Other revenues		93		1,828		-		1,921	
Total revenues		137,183		89,300		8,020		234,503	
Cost of sales		47,667		57,113		5,009		109,789	
	'								
Gross profit		89,516		32,187		3,011		124,714	
Advertising and promotion		25,150		6,595		384		32,129	
Contribution margin	\$	64,366	\$	25,592	\$	2,627		92,585	
Other operating expenses								32,573	
Operating income								60,012	
Other expense								22,513	
Provision for income taxes								14,212	
Income from continuing operations								23,287	
Income from discontinued operations, net of income tax								1,034	
Net income							\$	24,321	

During the three and nine month periods ended December 31, 2009, approximately 95.5% and 95.7%, respectively, of the Company's sales were made to customers in the United States and Canada while during the three and nine month periods ended December 31, 2008, approximately 96.2% and 96.4%, respectively, of sales were made to customers in the United States and Canada. Other than the United States, no individual geographical area accounted for more than 10% of net sales in any of the periods presented.

At December 31, 2009, substantially all of the Company's long-term assets were located in the United States of America and have been allocated to the operating segments as follows:

(In thousands)	C	Over-the- Counter Healthcare		Counter		Counter		Counter		Counter Househo		ousehold Cleaning	Personal Care		Co	nsolidated
Goodwill	\$	104,100	\$	7,389	\$	2,751	\$	114,240								
Intangible assets Indefinite-lived		334,750		119,821				454,571								
Finite-lived		67,851		33,579		5,827		107,257								
		402,601		153,400		5,827		561,828								
	\$	506,701	\$	160,789	\$	8,578	\$	676,068								
	-28-															

#### ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion of our financial condition and results of operations should be read together with the consolidated financial statements and the related notes included in this Quarterly Report on Form 10-Q, as well as our Annual Report on Form 10-K for the fiscal year ended March 31, 2009. This discussion and analysis may contain forward-looking statements that involve certain risks, assumptions and uncertainties. Future results could differ materially from the discussion that follows for many reasons, including the factors described in Part I, Item 1A., "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended March 31, 2009, as well as those described in future reports filed with the SEC. See also "Cautionary Statement Regarding Forward-Looking Statements" on page 47 of this Quarterly Report on Form 10-Q.

#### General

We are engaged in the marketing, sales and distribution of brand name over-the-counter healthcare, household cleaning and personal care products to mass merchandisers, drug stores, supermarkets and club stores primarily in the United States and Canada. We continue to use the strength of our brands, our established retail distribution network, a low-cost operating model and our experienced management team as a competitive advantage to grow our presence in these categories and, as a result, grow our sales and profits.

We have grown our brand portfolio by acquiring strong and well-recognized brands from larger consumer products and pharmaceutical companies, as well as other brands from smaller private companies. While the brands we have purchased from larger consumer products and pharmaceutical companies generally have had long histories of support and brand development, we believe that at the time we acquired them they were considered "non-core" by their previous owners and did not benefit from the focus of senior level management or strong marketing support. We believe that the brands we have purchased from smaller private companies have been constrained by the limited resources of their prior owners. After acquiring a brand, we seek to increase its sales, market share and distribution in both existing and new channels. We pursue this growth through increased spending on advertising and promotion, new marketing strategies, improved packaging and formulations and innovative new products.

# **Discontinued Operations and Sale of Certain Assets**

In October 2009, the Company sold certain assets related to the shampoo brands previously included in its Personal Care products segment to an unrelated third party. In accordance with the Discontinued Operations Topic of the Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC"), the Company reclassified the related assets as held for sale in the consolidated balance sheets as of March 31, 2009 and reclassified the related operating results as discontinued in the consolidated financial statements and related notes for all periods presented. The Company recognized a gain of \$253,000 on a pre-tax basis and \$157,000 net of tax effects on the sale in the quarter ended December 31, 2009.

The following table presents the assets related to the discontinued operations as of March 31, 2009 (in thousands):

	March 31, 2009
Inventory	\$ 1,0
Intangible assets	8,4
Total assets held for sale	\$ 9,5
	-29-

The following table summarizes the results of discontinued operations (in thousands):

	Three	Three Months Ended December 31			Nine Months Ended December 31			l December
	2	009		2008		2009		2008
Components of Income	-							_
Revenues	\$	651	\$	2,312	\$	4,998	\$	7,360
Income before income taxes		140		447		1,064		1,665

The total purchase price for the assets was \$9 million, subject to adjustments for inventory, with \$8 million received upon closing, and the remaining \$1 million to be paid on the first anniversary of the closing.

# Three Month Period Ended December 31, 2009 compared to the Three Month Period Ended December 31, 2008

#### Revenues (in thousands)

	2009				2008		1	Increase		
	Rev	enues/	%	Revenues		%	(Decrease)		%	
OTC Healthcare	\$	46,169	61.2	\$	47,595	61.0	\$	(1,426)	(3.0)	
Household Cleaning		27,265	36.1		28,138	36.1		(873)	(3.1)	
Personal Care		2,014	2.7		2,233	2.9		(219)	(9.8)	
	\$	75,448	100.0	\$	77,966	100.0	\$	(2,518)	(3.2)	

Revenues for 2009 were \$75.4 million, a decrease of \$2.5 million, or 3.2%, versus 2008. Revenues for all segments decreased versus the comparable period in the prior year. Revenues from customers outside of North America, which represent 4.5% of total revenues, increased by \$347,000 or 11.5% during 2009 compared to 2008 due to stronger shipments of eye care product to our Australian distributor.

In early February 2010, the Company was notified that its largest customer intended to discontinue the sale of *The Doctor's NightGuard* and *The Doctor's Brushpicks* due to that customer's initiative to reduce the number of vendors in the Oral Care category. Both products are included in our Over-the-Counter Healthcare Segment. Revenue and gross profit from these two products during the three months ended December 31, 2009 were approximately \$2.1 million and \$1.0 million, respectively. The Company requested a formal review by the customer of the products' performance in an effort to reverse the customer's decision; however, there can be no assurances that the customer's decision will be reversed or modified in any way or that sales of these products to that customer will resume at any level once discontinued.

#### **Over-the-Counter Healthcare Segment**

Revenues of the Over-the-Counter Healthcare segment decreased \$1.4 million, or 3.0%, during 2009 versus 2008. Revenue increases for *Clear Eyes*, *Murine Tears*, *Chloraseptic* and *Little Remedies* were offset by revenue decreases on *Allergen Block*, *Dermoplast and Murine Ear*. The increase in revenues for *Clear Eyes* was primarily the result of an increase in consumer consumption. The increase in revenues for *Murine Tears* was primarily the result of higher shipments to markets outside North America. *Chloraseptic* revenues increased as a result of shipments to customers in advance of the anticipated strong cough/cold flu season, although after a strong October, *Chloraseptic* consumer consumption for the period was down slightly. *Little Remedies* revenue increased due to strong consumer consumption of its non-medicated products. *Allergen Block* revenues decreased due to the non-recurrence during the current period of trade shipments to customers for the introductory advertising support that took place during the comparable prior year period. *Dermoplast* revenue decreased due to non-recurrence during the current period of promotional shipments of the institutional product that took place in the comparable prior year period. *Murine Ear*'s revenues decreased primarily as the result of slowing consumer consumption, particularly on *Earigate*.

# **Household Cleaning Segment**

Revenues for the Household Cleaning segment decreased \$873,000, or 3.1%, during 2009 versus 2008. A decrease in revenue for *Comet* was partially offset with increased revenue of *Spic and Span* and *Chore Boy. Comet's* revenues decreased primarily due to lower consumer demand for bathroom spray. *Chore Boy* revenues

increased as a result of timing of promotional shipments in September 2008 which were not repeated this year. *Chore Boy* consumer consumption declined for the period. *Spic and Span*'s revenues increased primarily due to timing of promotional shipments to the dollar store class of trade.

#### Personal Care Segment

Revenues of the Personal Care segment decreased \$219,000, or 9.8%, during 2009 versus 2008. The revenue decrease was primarily due to lower sales and higher trade allowances for *Cutex*.

#### **Gross Profit (in thousands)**

,	2009 ess Profit	%	G	2008 Fross Profit	%	ncrease ecrease)	%
OTC Healthcare	\$ 29,250	63.4	\$	30,703	64.5	\$ (1,453)	(4.7)
Household Cleaning	9,784	35.9		9,885	35.1	(101)	(1.0)
Personal Care	 773	38.4		898	40.2	(125)	(13.9)
	\$ 39,807	52.8	\$	41,486	53.2	\$ (1,679)	(4.0)

Gross profit for 2009 decreased \$1.7 million, or 4.0%, when compared with 2008. As a percent of total revenues, gross profit decreased from 53.2% in 2008 to 52.8% in 2009. The decrease in gross profit as a percent of revenues was primarily due to increased promotional allowances and higher distribution costs partially offset by lower obsolescence costs.

#### **Over-the-Counter Healthcare Segment**

Gross profit for the Over-the-Counter Healthcare segment decreased \$1.5 million, or 4.7%, during 2009 versus 2008. As a percent of Over-the-Counter Healthcare revenues, gross profit decreased from 64.5% during 2008 to 63.4% during 2009. The decrease in gross profit percentage was the result of higher trade allowances and unfavorable sales mix. The increase in trade allowances was primarily the result of an increase in trade promotion activity behind the *Allergen Block* products. The unfavorable sales mix was due to lower sales of *Allergen Block* during the period which has a lower product cost than the segment average.

#### **Household Cleaning Segment**

Gross profit for the Household Cleaning segment decreased by \$101,000, or 1.0%, during 2009 versus 2008. As a percent of Household Cleaning revenue, gross profit increased from 35.1% during 2008 to 35.9% during 2009. The increase in gross profit percentage was the result of decreased product costs for *Comet* partially offset by higher distribution costs for *Comet* due to transition to a new *Comet* powder supplier.

### **Personal Care Segment**

Gross profit for the Personal Care segment decreased \$125,000, or 13.9%, during 2009 versus 2008. As a percent of Personal Care revenues, gross profit decreased from 40.2% during 2008 to 38.4% during 2009. The decrease in gross profit percentage was due to higher trade allowances and distribution costs for *Cutex*.

# **Contribution Margin (in thousands)**

, ( , , , , , , , , , , , , , , , , , ,	 2009 ttribution Aargin	%	Co	2008 ontribution Margin	%	ncrease Decrease)	%
OTC Healthcare	\$ 24,104	52.2	\$	21,244	44.6	\$ 2,860	13.5
Household Cleaning	8,907	32.7		8,091	28.8	816	10.1
Personal Care	697	34.6		802	35.9	(105)	(13.1)
						_	
	\$ 33,708	44.7	\$	30,137	38.7	\$ 3,571	11.8

Contribution Margin, defined as gross profit less advertising and promotional expenses, increased \$3.6 million, or 11.8%, during 2009 versus 2008. The contribution margin increase was the result of a \$5.2 million, or 46.3%, decrease in advertising and promotional spending, partially offset by the decrease in gross profit as previously

discussed. The decrease in advertising and promotional spending was primarily attributable to decreases in media support in the Over-the-Counter Healthcare and Household Segments.

#### **Over-the-Counter Healthcare Segment**

Contribution margin for the Over-the-Counter Healthcare segment increased \$2.9 million, or 13.5%, during 2009 versus 2008. The contribution margin increase was the result of a \$4.3 million, or 45.6%, decrease in advertising and promotional spending, partially offset by the decrease in gross margin as previously discussed. The decrease in advertising and promotional spending was primarily attributable to a decrease in media support for the *Allergen Block* products from introductory media support levels in the prior year.

#### **Household Cleaning Segment**

Contribution margin for the Household Cleaning segment increased \$816,000, or 10.1%, during 2009 versus 2008. The contribution margin increase was the result of the decrease in gross profit as previously discussed, offset by a decrease in media support for *Comet Mildew Spray Gel*.

#### **Personal Care Segment**

Contribution margin for the Personal Care segment decreased \$105,000, or 13.1%, during 2009 versus 2008. The contribution margin decrease was primarily the result of the decrease in gross profit as previously discussed.

#### **General and Administrative**

General and administrative expenses were \$7.4 million for 2009 versus \$8.3 million for 2008. The decrease in expense was due to a reduction in legal expenses, favorable currency translation costs partially offset by higher incentive compensation costs.

### **Depreciation and Amortization**

Depreciation and amortization expense was \$2.6 million for 2009 versus \$2.3 million for 2008. Amortization was affected by the transfer of two trademarks in the Household Cleaning segment and one trademark in the Over-the-Counter segment, aggregating \$45.6 million, from indefinite-lived status to intangibles with finite lives. Commencing April 1, 2009, these intangibles are being amortized over a 20 year estimated useful life. This increase in amortization expense was partially offset by a reduction in amortization resulting from a trademark that became fully amortized at March 31, 2009, resulting in a net increase in depreciation and amortization expense of \$285,000 for the period.

#### **Interest Expense**

Net interest expense was \$5.6 million during 2009 versus \$7.1 million during 2008. The reduction in interest expense was primarily the result of a lower level of indebtedness combined with a reduction of variable interest rates on our senior debt. The average cost of funds decreased from 7.4% for 2008 to 6.8% for 2009 while the average indebtedness decreased from \$384.9 million during 2008 to \$328.8 million during 2009.

#### Income Taxes

The provision for income taxes during 2009 was \$7.8 million versus \$4.7 million during 2008. The effective tax rate during 2009 was 43.0% versus 37.9% during 2008. The increase in the effective rate was a result of a \$930,000 non-cash charge to deferred tax liability as a result of increasing the company's future effective tax rate from 37.9% to 38.3%. The increase in tax rate is a result of the divestiture of the shampoo business which increases the overall effective state tax rate on continuing operations. The new effective rate is applicable for tax years beginning after March 31, 2010.

### Nine month period Ended December 31, 2009 compared to the Nine month period Ended December 31, 2008

#### Revenues (in thousands)

activities (in anotherno)	Re	2009 evenues	%	 2008 Revenues	%	Increase Decrease)	%
OTC Healthcare	\$	137,829	59.8	\$ 137,183	58.5	\$ 646	0.5
Household Cleaning		83,725	36.3	89,300	38.1	(5,575)	(6.2)
Personal Care		9,087	3.9	8,020	3.4	1,067	13.3
	\$	230,641	100.0	\$ 234,503	100.0	\$ (3,862)	(1.6)

Revenues for 2009 were \$230.6 million, a decrease of \$3.9 million, or 1.6%, versus 2008. Revenues for both the Over-the-Counter Healthcare and Personal Care segments increased versus the comparable period. Revenues for the Household Cleaning segment declined during the period. Revenues from customers outside of North America, which represent 4.3% of total revenues, increased by \$1.1 million or 12.2% during 2009 versus 2008.

In early February 2010, the Company was notified that its largest customer intended to discontinue the sale of *The Doctor's NightGuard* and *The Doctor's Brushpicks* due to that customer's initiative to reduce the number of vendors in the Oral Care category. Both products are included in our Over-the-Counter Healthcare Segment. Revenue and gross profit from these two products during the nine months ended December 31, 2009 were approximately \$4.7 million and \$2.3 million, respectively. The Company requested a formal review by the customer of the products' performance in an effort to reverse the customer's decision; however, there can be no assurances that the customer's decision will be reversed or modified in any way or that sales of these products to that customer will resume at any level once discontinued.

#### **Over-the-Counter Healthcare Segment**

Revenues for the Over-the-Counter Healthcare segment increased \$646,000, or 0.5%, during 2009 versus 2008. Revenue increases for *Clear Eyes*, *Chloraseptic, Compound W, Little Remedies, Murine Tears* and *The Doctor*'s were partially offset by revenue decreases on *Allergen Block, Murine Ear*, *Wartner* and *Dermoplast. Clear Eyes* revenues increased primarily due to the launch of a new line of *Clear Eyes Tears* products and stronger shipments of the traditional and convenience size items. *Chloraseptic* revenues increased as the result of a stronger spring flu season driving consumer consumption and strong orders in advance of the winter cough/cold season. *Compound W* revenues increased due to increased consumer consumption, particularly behind the non-cryogenic products. *Little Remedies* revenues increased as the result of distribution gains and increased consumer consumption of its non-medicated pediatric products. *Murine Tears* revenues increased as the result of higher shipments to markets outside North America. *The Doctor*'s revenues increased due to an increase in advertising and the non-recurrence during the current period of promotional allowances related to the restage of the *Advanced Comfort NightGuard* dental protector that took place in 2008. *Allergen Block* revenues decreased as current year sales did not equal the pipeline orders that existed in 2008 as a result of promotions during the introductory period for the product. *Murine Ear*'s revenues decreased primarily as the result of slowing consumer consumption, particularly on *Earigate*. *Wartner*'s revenues decreased as the result of lost distribution and softness in the cryogenic segment of the wart treatment category.

#### **Household Cleaning Segment**

Revenues for the Household Cleaning segment decreased \$5.6 million, or 6.2%, during 2009 versus 2008. *Comet*'s revenues decreased primarily due to softer consumer consumption of bathroom spray. *Chore Boy* revenues declined as a result of weaker consumer consumption and lost distribution. *Spic and Span* revenues were flat versus 2008.

#### **Personal Care Segment**

Revenues for the Personal Care segment increased \$1.1 million, or 13.3%, during 2009 versus 2008. The revenue increase was driven by *Cutex* and was due to improving consumption in the nail polish remover category.

Gross	Profit	(in	thousands)

,	Gr	2009 oss Profit	%	Gı	2008 ross Profit	%	ncrease Decrease)	%
OTC Healthcare	\$	88,165	64.0	\$	89,516	65.3	\$ (1,351)	(1.5)
Household Cleaning		29,960	35.8		32,187	36.0	(2,227)	(6.9)
Personal Care		3,846	42.3		3,011	37.5	835	27.7
	\$	121,971	52.9	\$	124,714	53.2	\$ (2,743)	(2.2)

Gross profit during 2009 decreased \$2.7 million, or 2.2%, versus 2008. As a percent of total revenue, gross profit decreased from 53.2% in 2008 to 52.9% in 2009. The decrease in gross profit as a percent of revenues was primarily due to increased obsolescence costs and supplier transitional costs, partially offset by decreases in distribution costs.

#### **Over-the-Counter Healthcare Segment**

Gross profit for the Over-the-Counter Healthcare segment decreased \$1.4 million, or 1.5%, during 2009 versus 2008. As a percent of Over-the-Counter Healthcare revenues, gross profit decreased from 65.3% during 2008 to 64.0% during 2009. The decrease in gross profit percentage was primarily the result of higher promotional allowances, unfavorable sales mix and increased obsolescence costs partially offset by lower distribution costs. The increase in promotional allowances was primarily the result of an increase in trade promotion activity behind the *Allergen Block* products. The unfavorable sales mix was due to lower sales of *Allergen Block*, which has a lower product cost than the segment average. The increase in obsolescence costs was the result of short dated and slow moving eye care and *Allergen Block* inventory.

#### **Household Cleaning Segment**

Gross profit for the Household Cleaning segment decreased \$2.2 million, or 6.9%, during 2009 versus 2008. As a percent of Household Cleaning revenues, gross profit decreased from 36.0% during 2008 to 35.8% during 2009. The decrease in gross profit percentage was the result of higher promotional allowances across the segment and costs associated with the transition to a new *Comet* powder supplier, partially offset by decreased product costs for *Chore Boy* and *Comet* and lower distribution costs.

#### **Personal Care Segment**

Gross profit for the Personal Care segment increased \$835,000, or 27.7%, during 2009 versus 2008. As a percent of Personal Care revenues, gross profit increased from 37.5% during 2008 to 42.3% during 2009. The increase in gross profit percentage was due to lower promotional allowances and absence of obsolescence costs for *Cutex*.

#### Contribution Margin (in thousands)

Contribution Margin (in thousands)	 2009 ntribution Margin	%	Co	2008 ontribution Margin	%	Increase (Decrease)		%
OTC Healthcare	\$ 68,901	50.0	\$	64,366	46.9	\$	4,535	7.0
Household Cleaning	24,880	29.7		25,592	28.7		(712)	(2.8)
Personal Care	3,545	39.0		2,627	32.8		918	34.9
	\$ 97,326	42.2	\$	92,585	39.5	\$	4,741	5.1

Contribution Margin, defined as gross profit less advertising and promotional expenses, for 2009 increased \$4.7 million, or 5.1%, versus 2008. The contribution margin increase was the result of a \$7.5 million, or 23.3%, decrease in advertising and promotional spending, partially offset by the decrease in gross profit as previously discussed. The decrease in advertising and promotional spending was primarily attributable to decreases in media support for both the Over-the-Counter Healthcare and Household Cleaning segments, and market research for the Over-the-Counter Healthcare segment.

#### **Over-the-Counter Healthcare Segment**

Contribution margin for the Over-the-Counter Healthcare segment increased \$4.5 million, or 7.0%, during 2009 versus 2008. The contribution margin increase was the result of a \$5.9 million, or 23.4%, decrease in advertising and promotional spending, partially offset by the decrease in gross margin as previously discussed. The decrease in advertising and promotional spending was primarily attributable to a decrease in media support for the *Allergen Block* and *Murine Earigate* products, and a decrease in market research for *Clear Eyes*, *Chloraseptic* and *Compound W*.

#### **Household Cleaning Segment**

Contribution margin for the Household Cleaning segment decreased \$712,000, or 2.8%, during 2009 versus 2008. The contribution margin decrease was the result of the decrease in gross profit as previously discussed, partially offset by a decrease in media support for *Comet Mildew Spray Gel*.

#### Personal Care Segment

Contribution margin for the Personal Care segment increased \$918,000, or 34.9%, during 2009 versus 2008. The contribution margin increase was the result of the increase in gross profit as previously discussed and a modest reduction in trade promotion and market research for *Cutex*.

#### **General and Administrative**

General and administrative expenses were \$26.1 million for 2009 versus \$25.6 million for 2008. The increase in expense was due to a \$2.5 million net charge associated with the reduction in workforce and the CEO change, which took place in our second fiscal quarter, partially offset by favorable currency translation costs and a reduction in legal expenses.

#### **Depreciation and Amortization**

Depreciation and amortization expense was \$7.8 million for 2009 versus \$6.9 million for 2008. Amortization was affected by the transfer of two trademarks in the Household Cleaning segment and one trademark in the Over-the-Counter Healthcare segment, aggregating \$45.6 million, from indefinite-lived status to intangibles with finite lives. Commencing April 1, 2009, these intangibles are being amortized to operations over a 20 year estimated useful life. This increase in amortization expense was partially offset by a reduction in amortization resulting from a trademark that became fully amortized at March 31, 2009, resulting in a net increase in depreciation and amortization expense of \$856,000 for the period.

#### **Interest Expense**

Net interest expense was \$16.9 million during 2009 versus \$22.5 million during 2008. The reduction in interest expense was primarily the result of a lower level of indebtedness combined with a reduction of interest rates on our senior debt. The average cost of funds decreased from 7.6% for 2008 to 6.4% for 2009 while the average indebtedness decreased from \$394.6 million during 2008 to \$348.8 million during 2009.

#### **Income Taxes**

The provision for income taxes during 2009 was \$18.6 million versus \$14.2 million in 2008. The effective tax rate was 39.9% during 2009 versus 37.9% during 2008. The increase in the effective rate was a result of a \$930,000 non-cash charge to deferred tax liability as a result of increasing the company's future effective tax rate from 37.9% to 38.3%. The increase in tax rate is a result of the divestiture of the shampoo business which increases the overall effective state tax rate on continuing operations. The new effective rate is applicable for tax years starting after March 31, 2010.

# **Liquidity and Capital Resources**

#### Liquidity

We have financed and expect to continue to finance our operations with a combination of borrowings and funds generated from operations. Our principal uses of cash are for operating expenses, debt service, brand acquisitions, working capital and capital expenditures. Because we allowed our revolving credit facility to expire in April 2009 and due to the uncertain credit markets, the Company has increased its cash reserves by an additional \$30.0 million to provide an additional margin of liquidity. The Company expects to refinance its existing credit facility

and Senior Subordinated Notes on or before March 31, 2010; however, the Company cannot provide any assurance that such refinancing will be consummated by such date or at a future date.

(In thousands)		Nine Months Ended December 31							
		2009	2008						
Cash provided by (used for):		<u>'</u>							
Operating Activities	\$	50,490	\$	53,347					
Investing Activities		7,591		(4,588)					
Financing Activities		(59,000)		(26,903)					

#### **Operating Activities**

Net cash provided by operating activities was \$50.5 million for the nine month period ended December 31, 2009 compared to \$53.3 million for the comparable period in 2008. The \$2.8 million decrease in net cash provided by operating activities was the result of a decrease in working capital, primarily due to the increase in inventories, partially offset by increases in net income and deferred income taxes.

Consistent with the nine months ended December 31, 2008, the Company's cash flow from operations exceeded net income due to the substantial non-cash charges related to depreciation and amortization of intangibles, increases in deferred income tax liabilities resulting from differences in the amortization of intangible assets and goodwill for income tax and financial reporting purposes, the amortization of certain deferred financing costs, as well as stock-based compensation costs.

#### **Investing Activities**

Net cash provided by investing activities was \$7.6 million for the nine month period ended December 31, 2009 compared to net cash used for investing activities of \$4.6 million for the comparable period in 2008. The net cash provided by investing activities during the nine month period ended December 31, 2009 was primarily due to the divestiture of the shampoo business partially offset by the acquisition of property and equipment. Net cash used for investing activities during the nine month period ended December 31, 2008 was primarily due to the \$4.2 million settlement of a purchase price adjustment associated with the Wartner USA BV acquisition in 2006. The remainder was for the acquisition of property and equipment.

#### **Financing Activities**

Net cash used for financing activities was \$59.0 million for the nine month period ended December 31, 2009 compared to \$26.9 million for the comparable period in 2008. During the nine month period ended December 31, 2009, the Company repaid \$56.3 million of indebtedness in excess of normal maturities with cash generated from operations. This reduced our outstanding indebtedness to \$319.3 million at December 31, 2009 from \$378.3 million at March 31, 2009.

### **Capital Resources**

As of December 31, 2009, we had an aggregate of \$319.3 million of outstanding indebtedness, which consisted of the following:

- · \$193.3 million of borrowings under the Tranche B Senior Secured Term Loan Facility, and
- \$126.0 million of 9.25% Senior Subordinated Notes due 2012.

All loans under the senior secured term loan facility ("Senior Credit Facility") bear interest at floating rates, based on either the prime rate, or at our option, the LIBOR rate, plus an applicable margin. At December 31, 2009, an aggregate of \$193.3 million was outstanding under the Senior Credit Facility at an interest rate of 2.48%.

The Company uses derivative financial instruments to mitigate the impact of changing interest rates associated with its long-term debt obligations. Although the Company does not enter into derivative financial instruments for trading purposes, all of the Company's derivatives are straightforward over-the-counter instruments with liquid markets. The notional, or contractual, amount of the Company's derivative financial instruments is used to

measure the amount of interest to be paid or received and does not represent an actual liability. The Company accounts for these financial instruments as cash flow hedges.

In February 2008, the Company entered into an interest rate swap agreement in the notional amount of \$175.0 million, decreasing to \$125.0 million at March 26, 2009 to replace and supplement a \$50.0 million interest rate cap agreement that expired on May 30, 2008. Under this swap, the Company agreed to pay a fixed rate of 2.88% while receiving a variable rate based on LIBOR. The agreement terminates on March 26, 2010. The fair value of the interest rate swap agreement is included in either other assets or accrued liabilities at the balance sheet date. At December 31, 2009 and March 31, 2009, the fair values of the interest rate swap were \$794,000 and \$2.2 million, respectively. Such amounts were included in other accrued liabilities.

The Senior Credit Facility contains various financial covenants, including provisions that require us to maintain certain leverage ratios, interest coverage ratios and fixed charge coverage ratios. The Senior Credit Facility, as well as the Indenture governing the Senior Subordinated Notes, contain provisions that accelerate our indebtedness on certain changes in control and restrict us from undertaking specified corporate actions, including asset dispositions, acquisitions, payment of dividends and other specified payments, repurchasing the Company's equity securities in the public markets, incurrence of indebtedness, creation of liens, making loans and investments and transactions with affiliates. Specifically, we must:

- Have a leverage ratio of less than 4.0 to 1.0 for the quarter ended December 31, 2009, decreasing over time to 3.75 to 1.0 for the quarter ending December 31, 2010, and remaining level thereafter,
- Have an interest coverage ratio of greater than 3.0 to 1.0 for the quarter ended December 31, 2009, increasing over time to 3.25 to 1.0 for the quarter ending March 31, 2010, and remaining level thereafter, and
- Have a fixed charge coverage ratio of greater than 1.5 to 1.0 for the quarter ended December 31, 2009, and for each quarter thereafter until the quarter ending March 31, 2011.

At December 31, 2009, we were in compliance with the applicable financial and restrictive covenants under the Senior Credit Facility and the Indenture governing the Senior Subordinated Notes. Additionally, management anticipates that in the normal course of operations, the Company will be in compliance with the financial and restrictive covenants during the ensuing year.

At December 31, 2009, we had \$193.3 million outstanding under the Tranche B Term Loan Facility which matures in April 2011. We are obligated to make quarterly principal payments on the Tranche B Term Loan Facility equal to \$887,500, representing 0.25% of the initial principal amount of the term loan.

As a result of the expiration of certain credit facilities, the current economic environment and the state of the credit markets, the Company established and reached its goal of enhancing its liquidity position and used its strong cash flow generated from operations to build its cash reserves. Management estimates that cash reserves of approximately \$30.0 million are sufficient to provide adequate liquidity, allowing the Company to meet its current and future obligations as they come due. Accordingly, management made repayments against outstanding indebtedness of \$29.3 million in excess of scheduled maturities during the year ended March 31, 2009 and \$56.3 million in excess of scheduled maturities during the nine month period ended December 31, 2009. While management intends to replace these credit facilities during the ensuing year, the uncertainties of the credit markets could impede our ability to do so. As an example, the following factors could influence the amounts available to us and the interest rates associated with such an effort:

- $\cdot\quad$  A deterioration of the Company's earnings and its strong cash flows from operations,
- $\cdot$  Prevailing interest rates in the market for similar offerings by companies with comparable credit ratings,
- Total amount borrowed and the Company's intended use of such proceeds,

- · Ratio of amounts bearing fixed and variable rates of interest, and
- Total amount outstanding at the time, giving effect to the Company's ability to refinance its existing indebtedness.

In the current credit environment, management would expect the average interest rate associated with such a refinancing to be in excess of the Company's current average borrowing rate of 5.15%. However, we can give no assurances that financing will be available, or if available, that it can be obtained on terms favorable to us or on a basis that is not dilutive to our stockholders.

#### **Off-Balance Sheet Arrangements**

We do not have any off-balance sheet arrangements or financing activities with special-purpose entities.

#### Inflation

Inflationary factors such as increases in the costs of raw materials, packaging materials, purchased product and overhead may adversely affect our operating results. Although we do not believe that inflation has had a material impact on our financial condition or results from operations for the periods referred to above, a high rate of inflation in the future could have a material adverse effect on our business, financial condition or results from operations. The recent volatility in crude oil prices has had an adverse impact on transportation costs, as well as certain petroleum based raw materials and packaging material. Although the Company takes efforts to minimize the impact of inflationary factors, including raising prices to our customers, a high rate of pricing volatility associated with crude oil supplies may continue to have an adverse effect on our operating results.

#### **Critical Accounting Policies and Estimates**

The Company's significant accounting policies are described in the notes to the unaudited financial statements included elsewhere in this Quarterly Report on Form 10-Q, as well as in our Annual Report on Form 10-K for the fiscal year ended March 31, 2009. While all significant accounting policies are important to our consolidated financial statements, certain of these policies may be viewed as being critical. Such policies are those that are both most important to the portrayal of our financial condition and results from operations and require our most difficult, subjective and complex estimates and assumptions that affect the reported amounts of assets, liabilities, revenues, expenses or the related disclosure of contingent assets and liabilities. These estimates are based upon our historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results may differ materially from these estimates under different conditions. The most critical accounting estimates are as follows:

#### Revenue Recognition

We recognize revenue when the following revenue recognition criteria are met: (i) persuasive evidence of an arrangement exists; (ii) the product has been shipped and the customer takes ownership and assumes the risk of loss; (iii) the selling price is fixed or determinable; and (iv) collection of the resulting receivable is reasonably assured. We have determined that the transfer of risk of loss generally occurs when product is received by the customer, and, accordingly recognize revenue at that time. Provision is made for estimated discounts related to customer payment terms and estimated product returns at the time of sale based on our historical experience.

As is customary in the consumer products industry, we participate in the promotional programs of our customers to enhance the sale of our products. The cost of these promotional programs is recorded as advertising and promotional expenses or as a reduction of sales. Such costs vary from period-to-period based on the actual number of units sold during a finite period of time. We estimate the cost of such promotional programs at their inception based on historical experience and current market conditions and reduce sales by such estimates. These promotional programs consist of direct to consumer incentives such as coupons and temporary price reductions, as well as incentives to our customers, such as slotting fees and cooperative advertising. We do not provide incentives to customers for the acquisition of product in excess of normal inventory quantities since such

incentives increase the potential for future returns, as well as reduce sales in the subsequent fiscal periods.

Estimates of costs of promotional programs are based on (i) historical sales experience, (ii) the current offering, (iii) forecasted data, (iv) current market conditions, and (v) communication with customer purchasing/marketing personnel. At the completion of the promotional program, the estimated amounts are adjusted to actual results. Our related promotional expense for the year ended March 31, 2009 was \$17.4 million. We believe that the estimation methodologies employed, combined with the nature of the promotional campaigns, make the likelihood remote that our obligation would be misstated by a material amount. However, for illustrative purposes, had we underestimated the promotional program rate by 10% for the year ended March 31, 2009, our sales and operating income would have been adversely affected by approximately \$1.7 million. Net income would have been adversely affected by approximately \$1.1 million. Similarly, had we underestimated the promotional program rate by 10% for the three and nine month periods ended December 31, 2009, our sales and operating income would have been adversely affected by approximately \$512,000, and \$1.5 million, respectively. Net income would have been adversely affected by approximately \$318,000 and \$906,000 for the three and nine month periods ended December 31, 2009, respectively.

We also periodically run coupon programs in Sunday newspaper inserts or as on-package instant redeemable coupons. We utilize a national clearing house to process coupons redeemed by customers. At the time a coupon is distributed, a provision is made based upon historical redemption rates for that particular product, information provided as a result of the clearing house's experience with coupons of similar dollar value, the length of time the coupon is valid, and the seasonality of the coupon drop, among other factors. During the year ended March 31, 2009, we had 16 coupon events. The amount recorded against revenues and accrued for these events during the year was \$1.4 million; redemptions during the year were \$1.3 million. During the nine month period ended December 31, 2009, we had 19 coupon events. The amounts recorded against revenue and accrued for these events during the three and nine month periods ended December 31, 2009 were \$211,000 and \$1.1 million, respectively. The redemption amounts during the three and nine month periods ended December 31, 2009 were \$518,000 and \$1.1 million, respectively.

#### **Allowances for Product Returns**

Due to the nature of the consumer products industry, we are required to estimate future product returns. Accordingly, we record an estimate of product returns concurrent with the recording of sales. Such estimates are made after analyzing (i) historical return rates, (ii) current economic trends, (iii) changes in customer demand, (iv) product acceptance, (v) seasonality of our product offerings, and (vi) the impact of changes in product formulation, packaging and advertising.

We construct our returns analysis by looking at the previous year's return history for each brand. Subsequently, each month, we estimate our current return rate based upon an average of the previous six months' return rate and review that calculated rate for reasonableness giving consideration to the other factors described above. Our historical return rate has been relatively stable; for example, for the years ended March 31, 2009, 2008 and 2007, returns represented 3.8%, 4.4% and 3.3%, respectively, of gross sales. The increase in the returns rate from 2007 to 2008 of 1.1% was due to the voluntary withdrawal from the marketplace of *Little Remedies* medicated pediatric cough and cold products in October 2007. Had the voluntary withdrawal not occurred, the actual returns rate would have been 3.9%. For the three and nine month periods ended December 31, 2009, product returns represented 2.6% and 2.9% of gross sales, respectively. At December 31, 2009 and March 31, 2009, the allowance for sales returns was \$2.3 million and \$2.2 million, respectively.

While we utilize the methodology described above to estimate product returns, actual results may differ materially from our estimates, causing our future financial results to be adversely affected. Among the factors that could cause a material change in the estimated return rate would be significant unexpected returns with respect to a product or products that comprise a significant portion of our revenues in a manner similar to the *Little Remedies* voluntary withdrawal discussed above. Based upon the methodology described above and our actual returns' experience, management believes the likelihood of such an event remains remote. As noted, over the last three years our actual product return rate has stayed within a range of 4.4% to 3.3% of gross sales. An increase of 0.1% in our estimated return rate as a percentage of gross sales would have adversely affected our reported sales and operating income for the year ended March 31, 2009 by approximately \$357,000. Net income would have been adversely affected by approximately \$222,000. An increase of 0.1% in our estimated return rate as a percentage

of gross sales for the three and nine month periods ended December 31, 2009 would have adversely affected our reported sales and operating income by approximately \$88,000 and \$272,000, respectively, while our net income would have been adversely affected by approximately \$55,000 and \$169,000, respectively.

#### Allowances for Obsolete and Damaged Inventory

We value our inventory at the lower of cost or market value. Accordingly, we reduce our inventories for the diminution of value resulting from product obsolescence, damage or other issues affecting marketability equal to the difference between the cost of the inventory and its estimated market value. Factors utilized in the determination of estimated market value include (i) current sales data and historical return rates, (ii) estimates of future demand, (iii) competitive pricing pressures, (iv) new product introductions, (v) product expiration dates, and (vi) component and packaging obsolescence.

Many of our products are subject to expiration dating. As a general rule our customers will not accept goods with expiration dating of less than 12 months from the date of delivery. To monitor this risk, management utilizes a detailed compilation of inventory with expiration dating between zero and 15 months and reserves for 100% of the cost of any item with expiration dating of 12 months or less. At December 31, 2009 and March 31, 2009, the allowance for obsolete and slow moving inventory was \$2.6 million and \$1.4 million, representing 7.0% and 5.1%, respectively, of total inventory. Inventory obsolescence costs charged to operations were \$2.2 million for the year ended March 31, 2009, while for the three and nine month periods ended December 31, 2009, the Company recorded obsolescence costs of \$(70,000) and \$1.8 million, respectively. A 1.0% increase in our allowance for obsolescence at March 31, 2009 would have adversely affected our reported operating income and net income for the year ended March 31, 2009 by approximately \$273,000 and \$170,000, respectively. Similarly, a 1.0% increase in our allowance at December 31, 2009 would have adversely affected our reported operating income and net income for the three and nine month periods ended December 31, 2009 by approximately \$367,000 and \$228,000, respectively.

#### Allowance for Doubtful Accounts

In the ordinary course of business, we grant non-interest bearing trade credit to our customers on normal credit terms. We maintain an allowance for doubtful accounts receivable which is based upon our historical collection experience and expected collectibility of the accounts receivable. In an effort to reduce our credit risk, we (i) establish credit limits for all of our customer relationships, (ii) perform ongoing credit evaluations of our customers' financial condition, (iii) monitor the payment history and aging of our customers' receivables, and (iv) monitor open orders against an individual customer's outstanding receivable balance.

We establish specific reserves for those accounts which file for bankruptcy, have no payment activity for 180 days or have reported major negative changes to their financial condition. The allowance for bad debts amounted to 0.7% and 0.3% of accounts receivable at December 31, 2009 and March 31, 2009, respectively. Bad debt expense for the year ended March 31, 2009 was \$130,000, while during the three and nine month periods ended December 31, 2009, the Company recorded bad debt expense of \$50,000 and \$150,000, respectively.

While management believes that it is diligent in its evaluation of the adequacy of the allowance for doubtful accounts, an unexpected event, such as the bankruptcy filing of a major customer, could have an adverse effect on our future financial results. A 0.1% increase in our bad debt expense as a percentage of sales during the year ended March 31, 2009 would have resulted in a decrease in reported operating income of approximately \$303,000, and a decrease in our reported net income of approximately \$188,000. Similarly, a 0.1% increase in our bad debt expense as a percentage of sales for the three and nine month periods ended December 31, 2009 would have resulted in a decrease in reported operating income of approximately \$75,000 and \$231,000, respectively, and a decrease in our reported net income of approximately \$47,000 and \$143,000, respectively.

#### Valuation of Intangible Assets and Goodwill

Goodwill and intangible assets amounted to \$676.1 million and \$683.4 million at December 31, 2009 and March 31, 2009, respectively. At December 31, 2009, goodwill and intangible assets were apportioned among our three operating segments as follows:

(In thousands)	Over-the- Counter Healthcare		ousehold Cleaning	Personal Care		Co	nsolidated
Goodwill	\$	104,100	\$ 7,389	\$	2,751	\$	114,240
Intangible assets							
Indefinite-lived		334,750	119,821				454,571
Finite-lived		67,851	33,579		5,827		107,257
		402,601	153,400		5,827		561,828
	\$	506,701	\$ 160,789	\$	8,578	\$	676,068

Our *Clear Eyes, New-Skin, Chloraseptic, Compound W* and *Wartner* brands comprise the majority of the value of the intangible assets within the Over-The-Counter Healthcare segment. The *Comet, Spic and Span* and *Chore Boy* brands comprise substantially all of the intangible asset value within the Household Cleaning segment. *Cutex* comprised the majority of the intangible asset value within the Personal Care segment.

Goodwill and intangible assets comprise substantially all of our assets. Goodwill represents the excess of the purchase price over the fair value of assets acquired and liabilities assumed in a purchase business combination. Intangible assets generally represent our trademarks, brand names and patents. When we acquire a brand, we are required to make judgments regarding the value assigned to the associated intangible assets, as well as their respective useful lives. Management considers many factors, both prior to and after, the acquisition of an intangible asset in determining the value, as well as the useful life, assigned to each intangible asset that the Company acquires or continues to own and promote. The most significant factors are:

#### · Brand History

A brand that has been in existence for a long period of time (*e.g.*, 25, 50 or 100 years) generally warrants a higher valuation and longer life (sometimes indefinite) than a brand that has been in existence for a very short period of time. A brand that has been in existence for an extended period of time generally has been the subject of considerable investment by its previous owner(s) to support product innovation and advertising and promotion.

#### Market Position

Consumer products that rank number one or two in their respective market generally have greater name recognition and are known as quality product offerings, which warrant a higher valuation and longer life than products that lag in the marketplace.

### · Recent and Projected Sales Growth

Recent sales results present a snapshot as to how the brand has performed in the most recent time periods and represent another factor in the determination of brand value. In addition, projected sales growth provides information about the strength and potential longevity of the brand. A brand that has both strong current and projected sales generally warrants a higher valuation and a longer life than a brand that has weak or declining sales. Similarly, consideration is given to the potential investment, in the form of advertising and promotion, which is required to reinvigorate a brand that has fallen from favor.

#### · History of and Potential for Product Extensions

Consideration also is given to the product innovation that has occurred during the brand's history and the potential for continued product innovation that will determine the brand's future. Brands that can be continually enhanced by new product offerings generally warrant a higher valuation and longer life than a brand that has always "followed the leader".

After consideration of the factors described above, as well as current economic conditions and changing consumer behavior, management prepares a determination of the intangible's value and useful life based on its analysis.

Under accounting guidelines goodwill is not amortized, but must be tested for impairment annually, or more frequently if an event or circumstances change that would more likely than not reduce the fair value of the reporting unit below the carrying amount. In a similar manner, indefinite-lived assets are no longer amortized. They are also subject to an annual impairment test, or more frequently if events or changes in circumstances indicate that the asset may be impaired. Additionally, at each reporting period an evaluation must be made to determine whether events and circumstances continue to support an indefinite useful life. Intangible assets with finite lives are amortized over their respective estimated useful lives and must also be tested for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable and exceeds its fair value.

On an annual basis, during the fourth fiscal quarter, or more frequently if conditions indicate that the carrying value of the asset may not be recovered, management performs a review of both the values and useful lives assigned to goodwill and intangible assets and tests for impairment.

#### Finite-Lived Intangible Assets

As mentioned above, when events or changes in circumstances indicate the carrying value of the assets may not be recoverable, management performs a review to ascertain the impact of events and circumstances on the estimated useful lives and carrying values of our trademarks and trade names. In connection with this analysis, management:

- Reviews period-to-period sales and profitability by brand,
- · Analyzes industry trends and projects brand growth rates,
- · Prepares annual sales forecasts,
- Evaluates advertising effectiveness,
- · Analyzes gross margins,
- · Reviews contractual benefits or limitations,
- · Monitors competitors' advertising spend and product innovation,
- · Prepares projections to measure brand viability over the estimated useful life of the intangible asset, and
- · Considers the regulatory environment, as well as industry litigation.

Should analysis of any of the aforementioned factors warrant a change in the estimated useful life of the intangible asset, management will reduce the estimated useful life and amortize the carrying value prospectively over the shorter remaining useful life. Management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In the event that the long-term projections indicate that the carrying value is in excess of the undiscounted cash flows expected to result from the use of the intangible assets, management is required to record an impairment charge. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. The impairment charge is measured as the excess of the carrying amount of the intangible asset over fair value as calculated using the discounted cash flow analysis. Future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names could cause subsequent evaluations to utilize different assumptions.

#### Indefinite-Lived Intangible Assets

In a manner similar to finite-lived intangible assets, at each reporting period, management analyzes current events and circumstances to determine whether the indefinite life classification for a trademark or trade name continues to be valid. Should circumstance warrant a finite life, the carrying value of the intangible asset would then be amortized prospectively over the estimated remaining useful life.

The economic events experienced during the year ended March 31, 2009, as well as the Company's plans and projections for its brands, indicated that several of our brands could no longer support indefinite useful lives. Each of these brands incurred an impairment charge during the three month period ended March 31, 2009 and has been adversely affected by increased competition. Consequently, at April 1, 2009, management reclassified \$45.6 million of previously indefinite-lived intangibles to intangibles with definite lives. Management estimates the useful lives of these intangibles to be 20 years.

The fair values and the annual amortization charges of the reclassified intangibles are as follows (in thousands):

Intangible	M	Fair Value as of March 31, 2009		Annual Amortization		
Household Trademarks	\$	34,888	\$	1,745		
OTC Healthcare Trademark		10,717		536		
	\$	45,605	\$	2,281		

Management tests the indefinite-lived intangible assets for impairment by comparing the carrying value of the intangible asset to its estimated fair value. Since quoted market prices are seldom available for trademarks and trade names such as ours, we utilize present value techniques to estimate fair value. Accordingly, management's projections are utilized to assimilate all of the facts, circumstances and expectations related to the trademark or trade name and estimate the cash flows over its useful life. In performing this analysis, management considers the same types of information as listed above in regards to finite-lived intangible assets. Once that analysis is completed, a discount rate is applied to the cash flows to estimate fair value. Future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names could cause subsequent evaluations to utilize different assumptions.

#### Goodwill

As part of its annual test for impairment of goodwill, management estimates the discounted cash flows of each reporting unit, which is at the brand level, and one level below the operating segment level, to estimate their respective fair values. In performing this analysis, management considers the same types of information as listed above in regards to finite-lived intangible assets. In the event that the carrying amount of the reporting unit exceeds the fair value, management would then be required to allocate the estimated fair value of the assets and liabilities of the reporting unit as if the unit was acquired in a business combination, thereby revaluing the carrying amount of goodwill. In a manner similar to indefinite-lived assets, future events, such as competition, technological advances and reductions in advertising support for our trademarks and trade names could cause subsequent evaluations to utilize different assumptions.

#### Impairment Analysis

In estimating the value of trademarks and trade names, as well as goodwill at March 31, 2009, management applied a discount rate of 11.0%, the Company's estimated future weighted-average cost of funds, to the projected cash flows. This discounted cash flow methodology is a widely-accepted valuation technique utilized by market participants in the valuation process and has been applied consistently. In addition, we considered the Company's market capitalization at March 31, 2009, as compared to the aggregate fair values of our reporting units to assess the reasonableness of our estimates pursuant to the discounted cash flow methodology.

During the three month period ended March 31, 2009, as a direct consequence of the challenging economic environment, the dislocation of the debt and equity markets, and contracting consumer demand for our branded products, we recorded a non-cash charge in the amount of \$249.6 million related to the impairment of intangible assets and goodwill across the entire product line because the carrying amount of these "branded" assets exceeded their respective fair values. A summary of the impairment activity by segment is as follows:

(In thousands)	C	Over-the- Counter Healthcare		sehold aning	Personal Care		Co	nsolidated
Goodwill	\$	125,527	\$	65,160	\$	<u></u>	\$	190,687
Intangible assets								
Indefinite-lived		28,603		16,184				44,787
Finite-lived		12,420				1,696		14,116
		41,023		16,184		1,696		58,903
	\$	166,550	\$	81,344	\$	1,696	\$	249,590

The discount rate utilized in the analyses, as well as future cash flows may be influenced by such factors as changes in interest rates and rates of inflation. Additionally, should the related fair values of goodwill and intangible assets continue to be adversely affected as a result of declining sales or margins caused by competition, changing consumer preferences, technological advances or reductions in advertising and promotional expenses, the Company may be required to record additional impairment charges in the future. However, the Company was not required to recognize an additional impairment charge during the three or nine month periods ended December 31, 2009.

#### **Stock-Based Compensation**

The Compensation and Equity Topics of the FASB ASC requires the Company to measure the cost of services to be rendered based on the grant-date fair value of the equity award. Compensation expense is to be recognized over the period which an employee is required to provide service in exchange for the award, generally referred to as the requisite service period. Information utilized in the determination of fair value includes the following:

- · Type of instrument (i.e.: restricted shares vs. an option, warrant or performance shares),
- · Strike price of the instrument,
- · Market price of the Company's common stock on the date of grant,
- · Discount rates,
- · Duration of the instrument, and
- · Volatility of the Company's common stock in the public market.

Additionally, management must estimate the expected attrition rate of the recipients to enable it to estimate the amount of non-cash compensation expense to be recorded in our financial statements. While management uses diligent analysis to estimate the respective variables, a change in assumptions or market conditions, as well as changes in the anticipated attrition rates, could have a significant impact on the future amounts recorded as non-cash compensation expense. The Company recorded net non-cash compensation expense of \$2.4 million and \$1.1 million during the years ended March 31, 2009 and 2008, respectively. However, during the year ended March 31, 2009, management was required to reverse previously recorded stock-based compensation costs of \$193,000 and \$705,000 related to the May 2008 and 2007 grants, respectively, as it was determined that the Company would not meet the performance goals associated with such grants of restricted stock. During the year ended March 31, 2008, management for the same reasons was required to reverse previously recorded stock-based compensation costs of \$538,000, \$394,000 and \$166,000 related to the October 2005, July 2006 and May 2007 grants, respectively. The Company recorded non-cash compensation expense of \$810,000 and \$1.7 million during the three and nine month periods ended December 31, 2009, respectively, and non-cash compensation of \$671,000 and \$2.2 million during the three and nine month periods ended December 31, 2008, respectively. During the nine months ended December 31, 2009, management was required to reverse previously recorded stock-based compensation costs of \$564,000 recorded in 2009, as the service requirements related to those grants were not met.

#### **Loss Contingencies**

Loss contingencies are recorded as liabilities when it is probable that a liability has been incurred and the amount of such loss is reasonably estimable. Contingent losses are often resolved over longer periods of time and involve many factors including:

- · Rules and regulations promulgated by regulatory agencies,
- · Sufficiency of the evidence in support of our position,
- · Anticipated costs to support our position, and
- · Likelihood of a positive outcome.

#### **Recent Accounting Pronouncements**

In January 2010, the FASB issued authoritative guidance requiring new disclosures and clarifying some existing disclosure requirements about fair value measurement. Under the new guidance, a reporting entity should (a) disclose separately the amounts of significant transfers in and out of Level 1 and Level 2 fair value measurements and describe the reasons for the transfers, and (b) present separately information about purchases, sales, issuances, and settlements in the reconciliation for fair value measurements using significant unobservable inputs. This guidance is effective for interim and annual reporting periods beginning after December 15, 2009, except for the disclosures about purchases, sales, issuances, and settlements in the roll forward of activity in Level 3 fair value measurements. Those disclosures are effective for fiscal years beginning after December 15, 2010, and for interim periods within those fiscal years. The Company does not expect this guidance to have a material impact on its consolidated financial statements.

In August 2009, the FASB issued authoritative guidance to provide clarification on measuring liabilities at fair value when a quoted price in an active market is not available. In these circumstances, a valuation technique should be applied that uses either the quote of the liability when traded as an asset, the quoted prices for similar liabilities or similar liabilities when traded as assets, or another valuation technique consistent with existing fair value measurement guidance, such as an income approach or a market approach. The new guidance also clarifies that when estimating the fair value of a liability, a reporting entity is not required to include a separate input or adjustment to other inputs relating to the existence of a restriction that prevents the transfer of the liability. This guidance became effective beginning with the third quarter of the Company's 2010 fiscal year; however, the adoption of the new guidance did not have a material impact on the Company's financial position, results from operations or cash flows.

In June 2009, the FASB issued authoritative guidance to eliminate the exception to consolidate a qualifying special-purpose entity, change the approach to determining the primary beneficiary of a variable interest entity and require companies to more frequently re-assess whether they must consolidate variable interest entities. Under the new guidance, the primary beneficiary of a variable interest entity is identified qualitatively as the enterprise that has both (a) the power to direct the activities of a variable interest entity that most significantly impact the entity's economic performance, and (b) the obligation to absorb losses of the entity that could potentially be significant to the variable interest entity or the right to receive benefits from the entity that could potentially be significant to the variable interest entity. This guidance becomes effective for the Company's fiscal 2011 year-end and interim reporting periods thereafter. The Company does not expect this guidance to have a material impact on its consolidated financial statements.

In June 2009, the FASB established the FASB ASC as the source of authoritative accounting principles recognized by the FASB to be applied in the preparation of financial statements in conformity with generally accepted accounting principles. The new guidance explicitly recognizes rules and interpretive releases of the SEC under federal securities laws as authoritative accounting principles generally accepted in the United States of America ("GAAP") for SEC registrants. The new guidance became effective for our financial statements issued for the three and six month periods ending on September 30, 2009; however, the adoption of the new guidance in the Company's second quarter of the Company's 2010 fiscal year did not have a material impact on the Company's financial position, results from operations or cash flows.

In May 2009, guidance was issued under the topic Subsequent Events related to the accounting for and disclosure of events that occur after the balance sheet date, but before the financial statements are issued or are available to be issued. Additionally, this guidance requires the Company to disclose the date through which subsequent

events have been evaluated, as well as whether that date is the date the financial statements were issued or the date the financial statements were available to be issued. As discussed above, subsequent to the period end the Company sold certain personal care products to an unrelated third party. The related assets and operating results were reclassified accordingly.

The Financial Instruments Topic of the FASB ASC requires disclosures about the fair values of financial instruments at interim reporting periods in addition to annual financial statements. Effective April 1, 2009, the new guidance involves only enhanced disclosures and did not have any impact on the Company's financial position, results from operations or cash flows.

The Investments-Debt and Equity Securities topic of the FASB ASC modified the threshold a company must meet to avoid recognizing other-than-temporary impairments of debt securities purchased as investments. Effective April 1, 2009, the implementation of the new guidance did not have any impact on the Company's financial position, results from operations or cash flows.

The Derivatives and Hedging Topic of the FASB ASC requires a company with derivative instruments to disclose information to enable users of the financial statements to understand (i) how and why the company uses derivative instruments, (ii) how derivative instruments and related hedged items are accounted for, and (iii) how derivative instruments and related hedged items affect an entity's financial position, financial performance, and cash flows. Accordingly, the new guidance requires qualitative disclosures about objectives and strategies for using derivatives, quantitative disclosures about fair value amounts of and gains and losses on derivative instruments, and disclosures about credit-risk-related contingent features in derivative agreements. The implementation of the new guidance at January 1, 2009 involved enhanced disclosures of derivative instruments and the Company's hedging activities and did not have any impact on the Company's financial position, results from operations or cash flows.

In September 2006, the FASB issued guidance on Fair Value Measurements and Disclosures, which provides a single definition of fair value, establishes a framework for measuring fair value in GAAP and expands disclosures about fair value measurements in an effort to increase comparability related to the recognition of market-based assets and liabilities and their impact on earnings. The Fair Value Measurements and Disclosures guidance is effective for the Company's interim financial statements issued after April 1, 2008. However, on February 12, 2008, the FASB deferred the effective date of the guidance for one year for non-financial assets and non-financial liabilities that are recognized or disclosed at fair value in the financial statements on a nonrecurring basis. The implementation of the guidance, effective April 1, 2008, did not have a material effect on financial assets and liabilities included in the Company's consolidated financial statements as fair value is based on readily available market prices. Additionally, the implementation of the Fair Value Measurements and Disclosures guidance did not have a material effect as it relates to non-financial assets and non-financial liabilities that are recognized or disclosed at fair value in the Company's financial statements on a non-recurring basis.

Management has reviewed and continues to monitor the actions of the various financial and regulatory reporting agencies and is currently not aware of any other pronouncement that could have a material impact on the Company's consolidated financial position, results of operations or cash flows.

#### CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "PSLRA"), including, without limitation, information within Management's Discussion and Analysis of Financial Condition and Results of Operation. The following cautionary statements are being made pursuant to the provisions of the PSLRA and with the intention of obtaining the benefits of the "safe harbor" provisions of the PSLRA. Although we believe that our expectations are based on reasonable assumptions, actual results may differ materially from those in the forward-looking statements.

Forward-looking statements speak only as of the date of this Quarterly Report on Form 10-Q. Except as required under federal securities laws and the rules and regulations of the SEC, we do not have any intention to update any forward-looking statements to reflect events or circumstances arising after the date of this Quarterly Report on Form 10-Q, whether as a result of new information, future events or otherwise. As a result of these risks and uncertainties, readers are cautioned not to place undue reliance on forward-looking statements included in this Quarterly Report on Form 10-Q or that may be made elsewhere from time to time by, or on behalf of, us. All forward-looking statements attributable to us are expressly qualified by these cautionary statements.

These forward-looking statements generally can be identified by the use of words or phrases such as "believe," "anticipate," "expect," "estimate," "project," "will be," "will continue," "will likely result," or other similar words and phrases. Forward-looking statements and our plans and expectations are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, and our business in general is subject to such risks. For more information, see "Risk Factors" contained in Part I, Item 1A. of our Annual Report on Form 10-K for our fiscal year ended March 31, 2009. In addition, our expectations or beliefs concerning future events involve risks and uncertainties, including, without limitation:

- · General economic conditions affecting our products and their respective markets,
- · Our ability to increase organic growth via new product introductions or line extensions,
- · The high level of competition in our industry and markets (including, without limitation, vendor and SKU rationalization and expansion of private label of product offerings),
- · Our ability to invest in research and development,
- · Our dependence on a limited number of customers for a large portion of our sales,
- · Disruptions in our distribution center,
- · Acquisitions, dispositions or other strategic transactions diverting managerial resources, or incurrence of additional liabilities or integration problems associated with such transactions,
- · Changing consumer trends or pricing pressures which may cause us to lower our prices,
- · Increases in supplier prices and transportation and fuel charges,
- · Our ability to protect our intellectual property rights,
- · Shortages of supply of sourced goods or interruptions in the manufacturing of our products,
- · Our level of indebtedness, and ability to service our debt,
- · Any adverse judgments rendered in any pending litigation or arbitration,
- · Our ability to obtain additional financing, and
- · The restrictions imposed by our Senior Credit Facility and the indenture on our operations.

#### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to changes in interest rates because our Senior Credit Facility is variable rate debt. Interest rate changes generally do not affect the market value of the Senior Credit Facility, but do affect the amount of our interest payments and, therefore, our future earnings and cash flows, assuming other factors are held constant. At December 31, 2009 we had variable rate debt of approximately \$193.3 million related to our Tranche B term loan.

In February 2008, the Company entered into an interest rate swap agreement, effective March 26, 2008, in the notional amount of \$175.0 million, decreasing to \$125.0 million at March 26, 2009, to replace and supplement a \$50.0 million interest rate cap agreement that expired on May 30, 2008. Under the swap agreement, the Company pays a fixed rate of 2.88% while receiving a variable rate based on LIBOR. The fair value of the interest rate swap agreement of \$794,000 was included in other accrued liabilities at December 31, 2009. The agreement terminates on March 26, 2010.

Holding other variables constant, including levels of indebtedness, a one percentage point increase in interest rates on our variable rate debt would have an adverse impact on pre-tax earnings and cash flows for the twelve months ending December 31, 2010 of approximately \$1.9 million.

#### ITEM 4. CONTROLS AND PROCEDURES

#### **Disclosure Controls and Procedures**

The Company's management, with the participation of its Chief Executive Officer and the Chief Financial Officer, evaluated the effectiveness of the Company's disclosure controls and procedures, as defined in Rule 13a–15(e) of the Securities Exchange Act of 1934 ("Exchange Act") as of December 31, 2009. Based upon that evaluation, the Chief Executive Officer and Chief Financial Officer have concluded that, as of December 31, 2009, the Company's disclosure controls and procedures were effective to ensure that information required to be disclosed by the Company in the reports the Company files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms and that such information is accumulated and communicated to the Company's management, including the Company's Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

#### **Changes in Internal Control over Financial Reporting**

There have been no changes during the quarter ended December 31, 2009 in the Company's internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

#### PART II. OTHER INFORMATION

#### ITEM 1. LEGAL PROCEEDINGS

The legal proceedings in which we are involved have been disclosed previously in our Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and our Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2009 and September 30, 2009. Except as set forth below, there have been no material developments in our pending legal proceedings since September 30, 2009. For more information regarding our pending legal proceedings which we deem to be material to the Company, please see the legal proceedings disclosure contained in Part I, Item 3 of our Annual Report on Form 10-K for the fiscal year ended March 31, 2009 and Part II, Item 1 of our Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2009 and September 30, 2009.

#### Securities Class Action Litigation

After having given notice to class members, the defendants and the lead plaintiffs reached an agreement in principle to settle the litigation. On December 4, 2009, the settlement proposed by the defendants and the lead plaintiffs received final approval from the Court. Insurance covered the costs of all payments to the plaintiffs and their counsel. The class action and all claims made therein against us, our officers and directors and the other defendants in the action were dismissed with prejudice.

#### DenTek Oral Care, Inc. Litigation

On January 15, 2010, the Company and DenTek Oral Care, Inc. ("DenTek") reached a tentative agreement in principle to resolve the pending litigation between the Company and DenTek during a settlement conference before the Court. The settlement agreement remains subject to the negotiation and execution of a written settlement agreement acceptable to the Company and DenTek. As of the date of this Quarterly Report, a final settlement agreement was not yet executed by the parties. There can be no assurance that the Company and DenTek will ultimately execute a final settlement agreement and that the litigation will be resolved. In the event that a final settlement agreement is not executed or the litigation is not otherwise resolved, the litigation will resume. The Company's management believes that the counterclaims asserted by DenTek, Raymond Duane and C.D.S. Associates, Inc. ("CDS") are legally deficient and that it has meritorious defenses to the counterclaims. In the event the settlement is not consummated and the litigation resumes, the Company intends to vigorously defend against the counterclaims; however, the Company cannot reasonably estimate the potential range of loss, if any. The settlement agreement has no impact on the litigation pending between the Company and each of Raymond Duane, CDS and Kelly Kaplan.

In addition, the Company is involved from time to time in other routine legal matters and other claims incidental to its business. The Company reviews outstanding claims and proceedings internally and with external counsel as necessary to assess probability and amount of potential loss. These assessments are re-evaluated at each reporting period and as new information becomes available to determine whether a reserve should be established or if any existing reserve should be adjusted. The actual cost of resolving a claim or proceeding ultimately may be substantially different than the amount of the recorded reserve. In addition, because it is not permissible under GAAP to establish a litigation reserve until the loss is both probable and estimable, in some cases there may be insufficient time to establish a reserve prior to the actual incurrence of the loss (upon verdict and judgment at trial, for example, or in the case of a quickly negotiated settlement). The Company believes the resolution of routine matters and other incidental claims, taking into account reserves and insurance, will not have a material adverse effect on its business, financial condition, results from operations or cash flows.

#### ITEM 6. EXHIBITS

See Exhibit Index immediately following signature page.

## **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

# PRESTIGE BRANDS HOLDINGS, INC.

Date: February 9, 2010

By: /s/ PETER J. ANDERSON

Peter J. Anderson Chief Financial Officer (Principal Financial Officer and Duly Authorized Officer)

### **Exhibit Index**

- 31.1 Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
- 31.2 Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934.
- 32.1 Certification of Principal Executive Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.
- 32.2 Certification of Principal Financial Officer of Prestige Brands Holdings, Inc. pursuant to Rule 13a-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code.

#### CERTIFICATIONS

#### I, Matthew Mannelly, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Prestige Brands Holdings, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 9, 2010

/s/ Matthew Mannelly

Matthew Mannelly

Chief Executive Officer

#### CERTIFICATIONS

#### I, Peter J. Anderson, certify that:

- 1. I have reviewed this Quarterly Report on Form 10-Q of Prestige Brands Holdings, Inc.;
- 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
- 3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
- 4. The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
- 5. The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: February 9, 2010

/s/ Peter J. Anderson

Peter J. Anderson

Chief Financial Officer

# CERTIFICATION OF CHIEF EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Matthew Mannelly, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Brands Holdings, Inc. on Form 10-Q for the quarter ended December 31, 2009, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Brands Holdings, Inc.

#### /s/ Matthew Mannelly

Name: Matthew Mannelly
Title: Chief Executive Officer
Date: February 9, 2010

# CERTIFICATION OF CHIEF FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

I, Peter J. Anderson, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report of Prestige Brands Holdings, Inc. on Form 10-Q for the quarter ended December 31, 2009, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as applicable, and that information contained in such Quarterly Report fairly presents, in all material respects, the financial condition and results of operations of Prestige Brands Holdings, Inc.

/s/ Peter J. Anderson

Name: Peter J. Anderson Title: Chief Financial Officer Date: February 9, 2010